


Journal Pre-proof

European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for *Clostridioides difficile* infection in adults

Dr. J. van Prehn, dr. E. Reigadas, dr E.H. Vogelzang, dr. E. Bouza, prof., dr. A. Hristea, prof., dr B. Guery, prof., dr M. Krutova, dr T. Norén, dr F. Allerberger, prof., dr J. Coia, prof., dr A. Goorhuis, drs T.M. van Rossen, drs R.E. Ooijselaar, dr K. Burns, dr B.R. Scharvik Olesen, dr S. Tschudin-Sutter, prof., dr M.H. Wilcox, prof., dr M. Vehreschild, prof., dr F. Fitzpatrick, prof., dr E.J. Kuijper, prof., The guideline committee of the European Study Group on *Clostridioides difficile*



PII: S1198-743X(21)00568-1

DOI: <https://doi.org/10.1016/j.cmi.2021.09.038>

Reference: CMI 2715

To appear in: *Clinical Microbiology and Infection*

Received Date: 6 June 2021

Revised Date: 23 September 2021

Accepted Date: 30 September 2021

Please cite this article as: van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B, Krutova M, Norén T, Allerberger F, Coia J, Goorhuis A, van Rossen TM, Ooijselaar RE, Burns K, Scharvik Olesen BR, Tschudin-Sutter S, Wilcox MH, Vehreschild M, Fitzpatrick F, Kuijper EJ, The guideline committee of the European Study Group on *Clostridioides difficile*, European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for *Clostridioides difficile* infection in adults, *Clinical Microbiology and Infection*, <https://doi.org/10.1016/j.cmi.2021.09.038>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Draft 9 September 2021

**European Society of Clinical Microbiology and Infectious Diseases: 2021
update on the treatment guidance document for *Clostridioides difficile*
infection in adults.**

Dr. J. van Prehn, dr. E. Reigadas, dr. E.H. Vogelzang, prof. dr. E. Bouza, prof. dr. A. Hristea, prof. dr. B. Guery, dr. M. Krutova, dr. T. Norén, prof. dr. F. Allerberger, prof. dr. J. Coia, dr. A. Goorhuis, drs. T. M. van Rossen, drs. R. E. Ooijevaar, dr. K. Burns, dr. B.R. Scharvik Olesen, prof. dr. S. Tschudin-Sutter, prof. dr M. H. Wilcox, prof. dr. M. Vehreschild, prof. dr. F. Fitzpatrick and prof. dr. E.J. Kuijper.

The guideline committee of the European Study Group on *Clostridioides difficile*

ABSTRACT

Scope

In 2009, the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) published the first treatment guidance document for *Clostridioides difficile* infection (CDI). This document was updated in 2014. The growing literature on CDI antimicrobial treatment and novel treatment approaches, such as fecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, prompted the ESCMID study group on *C. difficile* (ESGCD) to update the 2014 treatment guidance document for CDI in adults.

Methods and Questions

Key questions on CDI treatment were formulated by the guideline committee and included: what is the best treatment for initial, severe, severe-complicated, refractory, recurrent and multiple recurrent CDI; what is the best treatment when no oral therapy is possible; can prognostic factors identify patients at risk for severe and recurrent CDI; and is there a place for CDI prophylaxis? Outcome measures for treatment strategy were: clinical cure, recurrence, and sustained cure. For studies on surgical interventions and severe-complicated CDI the outcome was mortality. Appraisal of available literature and drafting of recommendations was performed by the guideline drafting group. The total body of evidence for the recommendations on CDI treatment consists of the literature described in the previous guidelines, supplemented with a systematic literature search on randomized clinical trials and observational studies from 2012 and onwards. The Grades of Recommendation Assessment, Development and Evaluation (GRADE) system was used to grade the strength of our recommendations and the quality of the evidence. The guideline committee was invited to comment on the recommendations. The guideline draft was sent to external experts and a patients' representative for review. Full ESCMID endorsement was obtained after a public consultation procedure.

Recommendations

Important changes compared with previous guideline include but are not limited to: (1) metronidazole is no longer recommended for treatment of CDI when fidaxomicin or vancomycin are available, (2) fidaxomicin is the preferred agent for treatment of initial CDI and the first recurrence of CDI when available and feasible, (3) FMT or bezlotoxumab in addition to Standard of Care antibiotics (SoC) are preferred for treatment of a second or further recurrence of CDI, (4) bezlotoxumab in addition to SoC is recommended for the first recurrence of CDI when fidaxomicin was used to manage the initial CDI episode, and (5) bezlotoxumab is considered as an ancillary treatment to vancomycin for a CDI episode with high risk of recurrence when fidaxomicin is not available. Contrary to the previous guideline, in the current guideline emphasis is placed on risk for recurrence as a factor that determines treatment strategy for the individual patient, rather than the disease severity.

MANUSCRIPT

Introduction

After publication of the first treatment guidance document on *Clostridioides difficile* infection (CDI) in 2009 by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID), an update was published in 2014 [1]. The growing body of literature on CDI antimicrobial treatment and novel treatment approaches, such as fecal microbiota transplantation (FMT) and toxin-binding monoclonal antibodies, merits an update of the 2014 ESCMID guideline. This is supported by a literature review performed by the European Study group for *Clostridioides difficile* (ESGCD) for clinical trials published between 2013 and 2017 [2]. Indeed, the most recent guidance document of ESCMID's American counterparts the Society for Healthcare Epidemiology of America and the Infectious Diseases Society of America (SHEA/IDSA), provided important changes in the treatment recommendations for (recurrent) CDI [3]. The objective of this new document is: (1) to provide clinicians with: (1) an updated overview of currently available CDI treatment options, and (2) a systematic, transparent, evidence-based update on the optimal CDI treatment strategy based on patient and disease characteristics. The treatment options for CDI are subdivided into: the initial episode of CDI, severe CDI, severe-complicated CDI, refractory CDI, recurrent CDI, multiple recurrent CDI, and CDI prophylaxis. Management of paediatric patients with CDI is not included in this guideline. Diagnostic strategies and prevention and control measures are described in separate ESCMID guidance documents and are outside the scope of this document [4, 5].

Update methodology

Panel composition and guideline process

In 2018, a proposal for an update of *C. difficile* treatment was submitted to the ESCMID guidelines committee by the drafting group chair on behalf of the ESGCD. After approval of the proposal a small drafting group was constituted from ESGCD members to formulate questions to be answered and to perform a review of the literature. The questions were discussed and approved at the ESGCD group meeting at ECCMID 2019. Literature review and appraisal was supported by a clinical epidemiologist / methodologist. After literature review and appraisal, the small drafting group formulated draft recommendations. The recommendations were subsequently discussed and adjusted as appropriate by the larger ESGCD draft committee during a series of online meetings in February-March 2021. All

recommendations were agreed upon by consensus. Recommendations were based on the best available medical treatment and patient important outcomes below, and were not led by economic considerations. Possible economic restraints are acknowledged and alternatives are offered in case the treatment of first choice is not available or not feasible economically. The final draft of the guidance document was sent to the ESCMID guidelines manager for a public consultation procedure, and to experts from or affiliated with other infectious diseases organisations (see **Appendix**), and to a patients' representative for endorsement. Full ESCMID endorsement was obtained. All participating members were obliged to complete a Conflict of Interest form which was submitted to the ESCMID guidelines manager. We recommend that this guidance document is updated five years after publication, or sooner when new data becomes available that has a significant impact on the current recommendations. The ESGCD will evaluate the necessity to update the guideline at annual intervals.

Questions to be addressed

For the 2020 update on the guidance on *C. difficile* the ESGCD agreed to seek to answers for the following questions:

- I. What is the best treatment for initial CDI?
- II. What is the best treatment for severe and severe-complicated CDI?
- III. What is the best treatment for CDI when no oral treatment is possible?
- IV. What is the best treatment for refractory CDI?
- V. What is the best treatment for recurrent CDI?
- VI. What is the best treatment for multiple recurrences of CDI?
- VII. Can prognostic factors identify patients at risk for severe CDI?
- VIII. Can prognostic factors identify patients at risk for recurrent CDI?
- IX. Is there a place for prophylaxis for prevention of CDI?

The committee found it relevant to also consider the following issues:

- How best to define severe CDI.
- The principles for economic considerations.
- The timing of commencement of empiric treatment.
- The role of probiotics.
- The role of ancillary treatment strategies.
- Anti-CDI therapy during pregnancy.

- The treatment of patients at risk for severe CDI.
- The treatment of patients at risk for recurrent CDI.

Outcome measures and literature search

The guideline committee prospectively defined patient important outcome measures for treatment strategy as follows: clinical cure, recurrence, and sustained cure. For studies on surgical interventions and severe-complicated CDI the outcome was mortality. The outcome for prophylaxis studies was occurrence of CDI. The outcome for prognostic factors for severe and recurrent CDI was occurrence of severe and recurrent CDI, respectively. To answer the key questions formulated by the committee, four PICOs (Patients Intervention Comparison Outcome) were constructed (see **Supplementary data**). The resulting four literature searches were directed at (1) treatment strategies for CDI in adult patients, (2) prophylactic strategies for CDI, (3) identification of prognostic factors for severe CDI, and (4) identification of prognostic factors for recurrent CDI. The search strategies were constructed with the help of a trained librarian and can be found in the **Supplementary data**. PubMed, Embase, Emcare, Web of Science and COCHRANE Library databases were searched (Therapy and prophylaxis search September 24th 2019; Prognosis severe CDI October 2nd 2019; Prognosis recurrent CDI October 4th 2019). An update of the search was performed on March 11th 2021. The search was restricted to articles published in the English language. Meeting abstracts were excluded. The search on treatment strategy was limited to articles published since 2012; the evidence before 2012 was derived from the previous guideline. The search on prognostic factors was not limited by year of publication.

Selection process

Study eligibility was assessed in a two-step selection process. Two independent reviewers per search screened Title and Abstracts for possible eligible articles (treatment search JP and EJK; prognosis search TR and RO); any discrepancies were resolved by consensus. Full-text articles were retrieved for detailed assessment of suitability, risk of bias and data extraction (treatment JP/EV and ER/EB; prognosis TR and RO). Exclusion criteria were: no original data / meta-analysis, study population <18 years, no full-text available in the English language, and $N_{\text{population of interest}} < 30$, except for randomized clinical trials (RCTs). Prognostic studies with $N_{\text{outcome of interest}} < 30$ were also excluded. All steps were performed *in duplicate*. Cross-references of interest meeting the inclusions could be manually added to the included studies.

Data extraction and quality assessment.

Data was extracted using standardized data extraction forms. For the therapy search risk of bias assessment was based on an adapted version of the Cochrane Risk of Bias tool for RCTs , resulting in an individual classification for each study, see **Supplementary data** [6].

To assess the risk of bias for the prognostics studies, the Quality in Prognostic Research (QUIPS) tool was used [7]. The QUIPS tool is recommended by the Cochrane Prognosis Methods Group and appraises six domains: (1) study participation, (2) study attrition, (3) prognostic factor measurement, (4) outcome measurement, (5) study confounding and (6) statistical analysis and reporting. The analysis of prognostic factors was limited to those factors that were analysed in three or more separate studies to minimize the risk of publication bias. Variables that were part of the definitions of severe/severe-complicated CDI, and laboratory factors that are not part of 'standard care' were excluded.

Grading of the evidence

The findings of the systematic literature review were discussed with the members of the drafting group, and recommendations were formulated. Recommendations were preferably based on RCTs or prospective observational studies. When prospective data was not available, retrospective data was considered. Due to heterogeneity of studies (e.g definitions of severity of disease, duration of follow-up) no meta-analyses were performed. The guideline was developed according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The level of evidence for the recommendations was graded, taking into account any risk of bias, inconsistency, indirectness, imprecision, publication bias, that may upgrade or downgrade the level of evidence and the strength of recommendation [8]. The strength of recommendation is expressed as weak or strong). The quality of evidence is expressed as very low, low, moderate, or high. In instances where recommendations cannot be supported by evidence but guidance is deemed necessary by the committee, a good practice statement, i.e. expert opinion, is provided. For grading of prognostic factors, the starting point for the quality of evidence is based on the phase of investigation rather than the design of the studies: 1 = association (very low quality of evidence), 2 = independent association (low to moderate), and 3 = underlying mechanism (high) [9]. GRADE and summary of finding tables were generated using the GRADEpro GDT: GRADEpro Guideline Development Tool [McMaster University, 2020, developed by Evidence Prime, Inc.], available from grade.pro.org. The Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument was used for self-assessment of reporting [10].

Summary of Definitions

The definitions of the 2014 CDI treatment guideline remain largely unchanged, except for the definition of treatment response and severe CDI. The definitions are summarized below.

An **episode of CDI** is defined as (1) clinical findings compatible with CDI and microbiological evidence of *C. difficile* free toxins by enzyme immunoassay without reasonable evidence of another cause of diarrhoea **OR** (2) a clinical picture compatible with CDI and a positive nucleic acid amplification test (NAAT) preferably with a low cycle threshold (Ct) value [11, 12], or positive toxigenic *C. difficile* culture **OR** (3) pseudomembranous colitis as diagnosed during endoscopy, after colectomy or on autopsy, in combination with a positive test for the presence of toxigenic *C. difficile* [4, 13-16]. Diarrhea is defined as ≥ 3 loose stools, i.e. Bristol stool scale 6-7 [17], in 24 hours. Diagnostic methods vary between studies, and many studies used PCR-only detection of toxigenic *C. difficile*. Relying solely on NAAT may result in overdiagnosis of CDI, though in RCTs randomization should account for this.

Treatment response is present when (1) the patient has resolution of diarrhea, *and* has had a formed or normal stool for that patient, *with* maintenance of resolution for the duration of therapy and at least 48 hours after the end of treatment, *and* no further requirement for CDI therapy, **AND** (2) parameters of disease severity (clinical, laboratory, radiological) have improved and no new signs of severe disease have developed. In all other cases, treatment is considered a failure. A significant decrease in bowel movement frequency may also be considered a sign of (at least partial) response. Treatment response should be observed daily and evaluated after at least 3 days, assuming that the patient is not worsening on treatment. Treatment with metronidazole, in particular, may result in a clinical response only after 3–5 days [18-20]. After clinical response, it may take weeks for stool consistency and frequency to normalise [20, 21].

Refractory CDI is CDI not responding to recommended CDI antibiotic treatment, i.e. no response after 3-5 days of therapy. Refractory CDI can be part of either non-complicated or complicated CDI, which are described below.

Recurrence is present when CDI re-occurs within 8 weeks after a previous episode, provided the symptoms from the previous episode resolved after completion of initial treatment [14, 22]. However, follow-up duration for assessment of recurrence varies between studies, and many studies use 4- or 12-weeks. It is not feasible to distinguish recurrence due to relapse (renewed symptoms

from already present CDI) from recurrence due to reinfection in daily practice because genotyping is not readily available [23-27] .

Sustained cure is defined as treatment response without recurrence of CDI during follow-up.

The 2014 ESCMID guideline defined severe CDI as an episode of CDI with (one or more specific signs and symptoms of) severe colitis or a complicated course of disease, with significant systemic toxin effects and shock, resulting in need for ICU admission, colectomy or death [1, 22, 28, 29]. However, randomized clinical trials refer to the presence of one or more signs to define severe CDI, or use self-constructed or IDSA definitions. Patients with toxic megacolon, ileus or imminent surgery were typically excluded from these trials. For the current guideline and future purposes, the committee found the distinction between non-complicated and complicated CDI most relevant. To this end, the definitions of severe CDI has been changed and a severe-complicated category is introduced.

Severe CDI is characterized by one of the following factors at presentation: fever i.e. core body temperature $>38.5^{\circ}\text{C}$, marked leukocytosis i.e. leukocyte count $>15 \times 10^9/\text{L}$, and rise in serum creatinine, i.e. $>50\%$ above the baseline. Additional supporting factors, when available are: distension of the large intestine, pericolic fat stranding or colonic wall thickening (including low-attenuation mural thickening) at imaging.

Severe-complicated CDI (or fulminant CD) is defined by the presence of one of the following factors that needs to be attributed to CDI: hypotension, septic shock, elevated serum lactate, ileus, toxic megacolon, bowel perforation, or any fulminant course of disease (i.e rapid deterioration of the patient).

Results

Flowcharts of the literature search results for therapy and prophylaxis can be found in the **Supplementary data**. Detailed results of the literature search and grading of prognostics factors are found in a separate document that can be found at **medRxiv** <https://doi.org/10.1101/2021.06.22.21259313>. The literature search was last updated on March

11th 2021. After removal of duplicates, the therapy search resulted in 3565 unique references available for title/ abstract screening; 257 articles were assessed in more detail of which 171 articles were used for this guideline. A dedicated search for prophylaxis resulted in 290 additional references of which 11 were assessed in more detail; one extra study was included for prophylaxis [30], and one for CDI therapy [31]. The prognostic search on severe CDI yielded 1242 references; 126 studies were assessed in more detail and 76 were included for analysis [29, 32-106]; 12 more studies were manually added from cross-references [107-118] resulting in 88 studies for final analysis. The prognostic search on recurrent CDI yielded 1104 references; 105 studies were assessed in more detail and 36 were included for analysis [99, 106, 119-152]; seven cross-references were added [25, 108, 153-157], resulting in 43 studies for final analysis.

Summary of recommendations

A synthesis of treatment recommendations is shown in the treatment algorithm **Figure 1**. In addition to these therapeutic interventions, the following general measures are advised as described in the 2014 treatment guideline; [13, 22, 28, 158, 159]:

- **Discontinuation of unnecessary antimicrobial therapy**
- **Adequate replacement of fluid and electrolytes**
- **Avoidance of anti-motility medications**
- **Reviewing proton pump inhibitors (PPI) use**

Detailed results of recent (published 2012 and onwards) randomized clinical trials and prospective studies on initial, recurrent, severe, severe complicated and refractory CDI, and prophylaxis can be found in the **Supplementary Evidence Tables 1 to 4**. Grading and a summary of key findings for therapeutic options can be found in **Table 1 to 5**. Detailed results and evidence tables on prognostics factors can be found at medRxiv <https://doi.org/10.1101/2021.06.22.21259313>.

Recommendations

The recommendations regarding treatment and prognostic factors are described below per key question.

I. What is the best treatment for an initial episode of CDI?

- In case of non-severe CDI, we recommend to discontinue antibiotic therapy if possible with the inciting antibiotic and closely monitor the patient for 48 hours. *Good practice statement*
- For the initial episode of CDI we recommend fidaxomicin 200 mg twice daily for 10 days. *Strong (recommendation), Moderate (level of evidence)*
- When access to fidaxomicin is limited, it is reasonable to make a risk stratification for selected use. In this case, fidaxomicin is recommended whenever the clinicians deems the risk of recurrence high. This can be supported by an older age of the patient (>65years) plus the presence of one or more additional risk factor(s), i.e. healthcare-associated CDI, prior hospitalization in the last three months, use of concomitant antibiotics, PPI therapy (and a prior CDI episode). The risk of recurrence is assumed to be higher with more risk factors present. *Good practice statement*
- When fidaxomicin is not available or feasible, oral vancomycin 125 mg four times daily for 10 days is a suitable alternative. *Strong, High*
- Oral metronidazole 500 mg three times daily for 10 days should be used only when vancomycin and fidaxomicin are not available or feasible. *Strong, Moderate*
- The use of vancomycin 500 mg four times daily is not recommended. *Strong, Very low*
- Consider prolonged administration of fidaxomicin (extended fidaxomicin), i.e. 200 mg twice daily on days 1-5, and 200 mg once daily on alternate days on days 7-25, for an episode of CDI with increased risk of recurrence, especially in elderly hospitalized patients. *Weak, Low*
- Consider to add bezlotoxumab to oral standard of care treatment for an episode of CDI with increased risk of recurrence, when fidaxomicin is not available or feasible. In patients with a history of congestive heart failure, bezlotoxumab should be reserved for use when the benefits outweigh the risk. *Weak, Moderate*

Discontinue therapy with the inciting antimicrobial agent

As per 2014 ESCMID guideline [1], in case of non-severe CDI with a non-epidemic hypervirulent strain, i.e. in a non-epidemic situation, and CDI clearly induced by the use of antibiotics, it may be acceptable to discontinue therapy with the inciting antibiotic agent and observe the clinical response for 48 hours, providing that patients are followed very closely for any signs of clinical deterioration and placed on anti-CDI therapy immediately if this occurs. This advice is based on

clinical experience and an observational cohort [160]. In this cohort the sole intervention in a subgroup was cessation of the inciting antibiotic; this resulted in treatment response in 135 of 154 patients. Of note, the study was performed before increased incidence of hypervirulent *C. difficile* strains.

Metronidazole

Two RCTs published before 2000 showed equivalent efficacy for metronidazole and vancomycin, but conclusions are limited by small sample sizes ($n \leq 45$ per treatment group) and no details on severity of disease [161, 162]. Previous ESCMID and IDSA/SHEA guidelines recommended metronidazole as the initial choice for mild CDI [1, 3]. This was driven by a RCT that demonstrated a non-significant difference in cure rate for metronidazole versus vancomycin in a subgroup of patients with mild CDI ($n=81$, 90% vs. 98%), as opposed to cure rates for severe disease ($n=69$, 76% vs. 97%) [163]. A more recent analysis of two RCTs demonstrated inferiority of metronidazole compared with vancomycin ($n=555$, 73% vs. 81%), also in subanalyses of mild ($n=150$), moderate ($n=229$) and severe CDI ($n=157$) [164]. Also, in a prospective longitudinal cohort of 75 patients with uncomplicated initial CDI, treatment with metronidazole and diagnosis via EIA were the most robust predictors of CDI recurrence [165]. Therefore, metronidazole is no longer recommended as a first line agent for CDI treatment.

Fidaxomicin and vancomycin as Standard of Care (SoC)

A phase-3 RCT conducted in the US and Canada compared fidaxomicin to vancomycin and found similar cure rates ($n=596$, 88% vs. 86%), but an absolute risk reduction of 9.9% for recurrence at 4 weeks in favour of fidaxomicin ($n=518$, recurrence 15% vs. 25%, reduction 95% CI -16.6 to -2.9) [166]. Likewise, non-inferiority for cure was shown in a RCT conducted in the US, Canada and Europe, and a 14.2% reduction of recurrence at 4 weeks ($n=244$, recurrence 13% vs. 27% reduction 95% CI -21.4 to -6.8) [167]. Of note, the recurrence rates for CDI caused by BI/NAP1/027 epidemic strains were either similar [166], or the benefit of fidaxomicin was non-significant [167]. A post-hoc subgroup analysis of patients with cancer in both trials found higher initial cure for fidaxomicin compared with vancomycin ($n=183$, 85% vs. 74%), driven by a decreased cure rate with vancomycin in this subgroup [168]. Two small(er) RCTs were conducted but were graded a lower Quality of Evidence [169, 170]. Fidaxomicin has the narrowest spectrum of activity, and is less detrimental to the bacterial gut microbiome [171, 172], which in the setting of CDI is preferred. It must be noted that fidaxomicin has higher acquisition costs than vancomycin, which may limit widespread prescription. The decreased recurrence rate and subsequent decreased re-hospitalisation rate

partially offsets the higher acquisition costs of fidaxomicin, and may result in cost-effectiveness [173-175], although many cost-effectiveness studies are co-authored by employees of pharmaceutical companies [176-178], or funded by the manufacturer or holder of market authorisation [179, 180]. In general, the committee agreed that medical aspects should guide our recommendations and that the best available treatment should be recommended, however, limited resources must also be acknowledged. Therefore, we have chosen to: (1) recommended fidaxomicin as the preferred option because on reduced recurrence rates, (2) advise vancomycin as a suitable alternative when the preferred option is not feasible or available, (3) recommend metronidazole only when fidaxomicin and vancomycin are not available, and (4) offer a stratification strategy for selected use of fidaxomicin.

High dose vancomycin

There is insufficient evidence to support the use of high dose oral vancomycin 500 mg four times daily [181]. The standard dose of 125 mg four times daily already results in high intraluminal levels [182], and high dose vancomycin increases risk of possible adverse effects, e.g. systemic levels of vancomycin [183]. Additionally, concerns regarding increased antibiotic selection pressure resulting in resistance selection (e.g. vancomycin-resistant enterococci-VRE) remain.

Extended fidaxomicin

A multinational European open-label RCT compared an extended fidaxomicin regime (200 mg oral tablets, twice daily on days 1–5, then once daily on alternate days on days 7–25) to vancomycin in hospitalised patients aged 60 years or older [184]. For randomization, patients were stratified by baseline CDI severity, cancer presence, age (≥ 75 years vs < 75 years), and number of previous CDI episodes. Sustained clinical cure at 30 days was 70% in 177 patients that received extended fidaxomicin, of which 21% had one or two CDI episodes within the prior 3 months; sustained cure with vancomycin was 59%. It should be also noted that, in contrast to the fidaxomicin RCTs with a standard regime, the difference in sustained cure between fidaxomicin and vancomycin was more pronounced in patients with *C. difficile* PCR ribotype 027: 39.1 (95% CI 13.2 to 64.9). Further, it is of interest that although the mean age of patients in this study was 75 years, sustained cure rates were comparable to previous reports [166, 167], and the recurrence rate at 90 days was only 6%. A direct comparison with fidaxomicin administered for 10 days would have increased the level of evidence supporting the use of extended fidaxomicin. The committee agrees that an extended (off-label) approach may be considered for treatment of the population studied in the RCT, i.e. older patients who are at risk for CDI recurrence.

Bezlotoxumab

Bezlotoxumab is a monoclonal antibody directed against *C. difficile* toxin B. Addition of bezlotoxumab to standard of care (SoC) CDI antibiotics resulted in similar cure rates but a 10% reduced risk of recurrences in the placebo controlled MODIFY-I and II trials [185]. It should be noted that the proportion of patients receiving vancomycin as SoC was 48%, while fidaxomicin was given in 4%. The benefit of adding bezlotoxumab to fidaxomicin is therefore unclear. Post-hoc analysis of pre-specified risk factors revealed that these were appropriate to identify patients at risk for rCDI [186]. Reduction of recurrence was 25% (95%CI -39 to -9) in patients with ≥ 3 risk factors, and 2% (-11 to 7) in patients with no risk factors. Prespecified risk factors included age ≥ 65 years, history of CDI in the previous 6 months, immunocompromised, severe course of CDI and CDI caused by *C. difficile* strains associated with poor outcomes (ribotype 027, 078, or 244). Caution should be exercised with prescription of bezlotoxumab to patients with a history of congestive heart failure. In these patients, heart failure was reported more commonly compared to the placebo group, 12.7% (15/118) versus 4.8% (5/104) and more deaths were reported, 19.5% (23/118) versus 12.5% (13/104) respectively [187]. Even though the acquisition costs of bezlotoxumab are even higher than for fidaxomicin, Markov modelling - with its inherent limitations - indicates that bezlotoxumab might be cost-effective [175, 188, 189]. Of note, two of these studies were financially supported by the manufacturer of bezlotoxumab. Considering the higher acquisition costs and no clear benefit when comparing to fidaxomicin for the treatment of CDI, we have recommended the addition of bezlotoxumab to SoC for an episode of CDI with increased risk of recurrence, when fidaxomicin is not available or feasible. The quality of evidence was graded moderate because the population of interest was studied in a *post hoc* analysis [186]. In patients with a history of congestive heart failure, bezlotoxumab should be reserved for use when the benefits outweigh the risk.

Other agents

Ridinilazole (SMT19969) is a potential CDI antibiotic of interest and was superior to vancomycin for sustained cure at the 10% level in a phase 2 RCT [190]. A comparative trial with fidaxomicin (NCT2784002) is currently enrolling patients [191]. Development of cadazolid, tolevamer and surotomycin were halted after failure to demonstrate non-inferiority in RCTs [164, 192, 193]. LFF571 was non-inferior to vancomycin for cure in a phase 2 RCT, but its development was discontinued [194].

II. What is the best treatment for severe and severe-complicated CDI?

- **Options for treatment of any severe and severe-complicated CDI episode include vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days. There is no data supporting the superiority of one over the other. *Good practice statement***
- **For severe CDI, routine addition of i.v. metronidazole to oral SoC therapy is not recommended. *Weak against, Very Low***
- **When a patient is deteriorating or progressing to severe-complicated CDI while on anti-CDI antibiotic therapy, addition of i.v. tigecycline 50 mg twice daily (100 mg loading dose) may be considered on a case-by-case basis. *Weak, Very Low***
- **Consult a surgeon for any severe-complicated case. *Good practice statement***
- **Total abdominal colectomy might be prevented by partial colectomy or loop ileostomy. *Weak, Very Low***

Antibiotic treatment

The previous guideline included a different antibiotic regime for non-severe and severe initial CDI. This was based on the non-inferiority of metronidazole in mild disease [163]. Since metronidazole is no longer a preferred agent for treatment of any CDI episode, the distinction between non-severe and severe course of the disease has become less relevant. In the current guideline, the most relevant distinction is between non-severe/severe CDI and severe complicated CDI.

Vancomycin is the traditional agent for oral antibiotic therapy in severe and severe complicated CDI. The use of vancomycin in these groups is based on historical grounds. In the subgroup of patients with severe CDI in two pivotal RCTs (n=235 and n=124), oral vancomycin and fidaxomicin had similar outcomes in terms of cure rate and recurrence rate [166, 167]. Patients with severe complicated disease were excluded from these trials. The optimal antibiotic therapy for critically ill patients, i.e. severe complicated CDI is unknown, as these patients are typically excluded from prospective (randomized) clinical trials that investigate CDI agents. A retrospective multinational post-authorization study of fidaxomicin (n=271) found diarrhoea response rates ranging from 68% to 82% and recurrence rates ranging from 14% to 19% in patients with concomitant Inflammatory Bowel Disease (IBD), fulminant CDI, moderate-to-severe hepatic impairment and severe renal impairment [195]. A propensity-score matched cohort study compared 213 fidaxomicin to 639 vancomycin courses and found similar outcomes in patients with severe disease [196]. This study did not include fulminant CDI or toxic megacolon. A single centre retrospective analysis found that fidaxomicin

response among patients admitted to the critical care unit was similar to patients admitted to general wards [197]. Another retrospective study included a subset of 16 patients with severe-complicated CDI of which 11 were initially cured and three had a recurrence [198]. Mortality was 44% in this subset, and 75% of patients were prescribed fidaxomicin after failure of another agent. Overall, there are no data that demonstrate superiority of fidaxomicin or vancomycin over the other for severe and severe-complicated CDI.

Intravenous metronidazole

There is no new evidence that supports the routine addition of i.v. metronidazole in severe CDI. A large retrospective analysis (n=2114) found no association between dual therapy and 90-day mortality, colectomy and CDI recurrence in patients with non-severe (n=727), severe (n=861) and fulminant CDI (n=526) [199]. A prospective observational trial suggests that i.v. metronidazole monotherapy may result in a higher mortality rate when compared with oral metronidazole or vancomycin treatment [200]. Cure rate (52%), recurrence rate (50%) and 30-day mortality (38%) in patients with mild CDI treated with i.v. metronidazole (n=42) were disappointing. However, choice of treatment was at the discretion of the treating clinician and therefore results are prone to bias. A recent retrospective analysis of 138 patients found that addition of i.v. metronidazole to oral vancomycin was not associated with better clinical outcomes in severe non-fulminant CDI in ICU patients [201]. In contrast, a retrospective study in patients admitted to the ICU supports the suggestion that addition of i.v. metronidazole to oral CDI therapy in critically ill patients might be beneficial [202]. Forty-four patients treated with monotherapy were matched to 44 patients with combination therapy, based on APACHE II score. Mortality was 20% lower in the i.v. metronidazole combination therapy group. However, there were more oncological patients and patients with neutropenia in the monotherapy group. Overall, we do not recommend routine addition of i.v. metronidazole to oral antibiotic therapy in severe CDI. For use of i.v. metronidazole, we refer to section III: CDI treatment when no oral treatment is possible.

Intravenous tigecycline

Tigecycline shows in vitro activity against *C. difficile* and intravenous tigecycline has been studied in observational cohorts. No (randomized) clinical trial has investigated tigecycline for treatment of CDI. A retrospective single centre study compared i.v. tigecycline monotherapy (n=45) to oral vancomycin + metronidazole i.v. (n=45) in severe CDI and found a better cure rate for tigecycline monotherapy (50 mg twice daily) after a loading dose (100 mg), 76% versus 53%, and less CDI sepsis, 16% versus 40% [203]. The majority of patients received tigecycline as a last resort therapy after

failure of standard antibiotics. In contrast, a recent propensity matched study found no benefit for the addition of tigecycline (n=62) to vancomycin (n=204) with OR 0.92 (95% CI 0.6-1.44) for favourable outcome with tigecycline [204], although in the propensity score analysis, a small sample size was included (43 pairs, 86 patients). A recent literature review concluded that tigecycline might be considered as potential therapeutic option for severe CDI cases, although this is based on retrospective observational studies [205]. Nevertheless, the committee concludes that tigecycline merits consideration when a patient is deteriorating or progressing to severe-complicated disease.

Surgery for severe-complicated CDI

Analysis of a nationwide US database (2007-2015) confirms that 30-day mortality in patients that underwent total or partial colectomy for CDI is high, 37% and 35% respectively. It is difficult to provide an evidence-based recommendation on the optimal timing of surgery for severe complicated CDI. A review from 2010 suggests that colectomy is associated with a lower mortality than continued medical treatment when the patient is no longer improving [206]. Total abdominal colectomy (TAC) is the standard when surgery is needed, but might be prevented by partial colectomy or loop ileostomy. Loop ileostomy (LI) for CDI includes intraoperative colonic lavage with warmed polyethylene glycol 3350/electrolyte solution via the ileostomy, with postoperative antegrade instillation of vancomycin flushes *via* the ileostomy. Using the aforementioned protocol, the first study that described LI found a lower mortality when compared to a historical cohort: 19% vs 50% [207]. Unfortunately, an RCT aimed at comparing LI to TAC (NCT01441271) was terminated due to hampered inclusion. A recent retrospective multicentre study also found a survival benefit for LI (mortality 17% vs 40%, n=98) [208]. In contrast, two national US database reviews (2011-2016 and 2011-2015) did not demonstrate a mortality benefit (mortality LI 36% vs. 31% TAC, n=47 vs. n=410; and LI 26% vs 31% TAC, n=613 and n=2408) [209, 210]. Although the quality of evidence is low and reported mortality benefits are conflicting, partial colectomy or loop ileostomy should be considered to prevent TAC. The committee considers it good clinical practice to consult a surgeon for any severe complicated case.

III. What is the best treatment for CDI when no oral treatment is possible?

- **When oral therapy is not possible, attempt intraluminal (gastroduodenal or coloscopic) delivery of vancomycin or fidaxomicin** *Good practice statement*

- **and consider adjunctive treatment with i.v. metronidazole 500 mg 3 times daily or i.v. tigecycline 50 mg two times daily (100 mg loading dose).** *Weak, Very Low*

The evidence regarding i.v. metronidazole and i.v. tigecycline is discussed in the previous section (severe and severe-complicated CDI). It should be noted that the standard of care treatment for CDI is based on high intraluminal concentrations of the active agents which are minimally absorbed in the gastro-intestinal tract. Therefore, when oral treatment with vancomycin or fidaxomicin is not possible, intraluminal delivery should be attempted. The evidence for intraluminal vancomycin is limited to case series and dosages range from 250 mg once daily to 1 g QID [211]. There is no data on intraluminal fidaxomicin delivery. It seems reasonable use standard oral dosages for intraluminal delivery. Addition of an intravenous antibiotic might be beneficial on a theoretical basis when low intraluminal concentrations of oral CDI agents are expected.

IV. What is the best treatment for refractory CDI?

Consideration of adjunctive intravenous treatment has been described in the previous sections. Here we will advise on refractory non-complicated CDI and the role of surgery and FMT in refractory complicated CDI.

- **When non-complicated CDI is not responding to CDI treatment and the patient is not deteriorating or progressing to complicated CDI, carefully re-evaluate the diagnosis of CDI and consider an alternative diagnosis.** *Good practice statement*
- **Consult a surgeon as soon as a patient's condition is deteriorating and the patient is not responding to CDI treatment.** *Good practice statement*
- **FMT may be a rescue therapy for patients with severe complicated CDI that (1) have deteriorated despite CDI antibiotic treatment and (2) for whom surgery is not feasible. The risk-benefit analysis of FMT and/or surgical management should be taken on a case-by-case basis and discussed by the multidisciplinary team.** *Weak, Very Low*

Non-complicated refractory CDI

For patients with non-complicated CDI who are not responding to standard of care oral treatment, who do not have a deteriorating condition, and are not progressing to complicated CDI, the diagnosis of CDI should be reconsidered as vancomycin and fidaxomicin resistance is very rare in Europe. The susceptibility percentages for vancomycin and fidaxomicin were 96.8% and 100%, respectively, in a pan-European study that included 918 *C. difficile* isolates [212]. In addition, an alternative diagnosis or underlying pathology in combination with *C. difficile* colonisation, may be present in a significant portion of patients suspected for CDI. For example, a paper on the experiences of a multidisciplinary expert panel that assesses applications for FMT reported that 27% of requests were rejected; the majority because of *C. difficile* colonisation with diarrhea due to another cause [213]. In an outpatient setting, non-adherence to the prescribed treatment should also be considered.

The role of surgery in severe-complicated refractory CDI

The committee finds a multidisciplinary approach to the management of patients refractory to antibiotic CDI treatment of utmost importance. Thus, a surgical opinion should be sought early in the process, i.e. as soon as a patient's condition is deteriorating and the patient is not responding to CDI treatment. See the previous section for our conclusion on TAC, partial colectomy or loop ileostomy.

The role of FMT in severe-complicated refractory CDI

Fecal microbiota transplantation (FMT) has become an accepted treatment for multiple recurrent CDI [1, 3]. As experience with FMT increases, it has become apparent that there might be a role for FMT in severe complicated refractory CDI. An observational cohort study found an 87% cure rate at one month for severe complicated refractory CDI [214]. In this study, patients with severe CDI (n=19) and severe complicated CDI (n=38) were offered FMT instead of surgery after a multidisciplinary evaluation [214]. Vancomycin was continued after FMT, and 5 days-post FMT the treatment response was evaluated. Sequential FMT was performed when necessary. Treatment success at 1 month was 100% for severe and 87% for severe-complicated disease. Survival rate was 95% at 1 month and 77% at 3 months. Thirty patients had a single FMT to reach clinical cure. A small RCT in patients with therapy refractory severe (n=23) and severe complicated (n=33) CDI compared bowel preparation plus a single FMT followed by 14 days oral vancomycin to multiple FMT infusions, and found cure rates of 75% and 100%, respectively [215]. Although patients were randomized, a control group with maximum conservative or surgical treatment was lacking. Both studies that are mentioned above indicate that multiple FMT infusions may be warranted, using continued presence of pseudomembranes as an indicator for the need for an additional FMT infusion [214, 215]. Although not included in our search strategy, it is important to note that a prospective series of 15

patients indicated less favourable results with 87% response at day 7, but 33% sustained cure at day 30, with one colectomy and two (of five) deaths attributable to CDI [216]. Although the level of evidence is very low, considering the high mortality associated with surgical therapy for CDI and the fact that some patients are too ill to be surgical candidates, the committee believes there is a place for FMT in patients with refractory severe complicated CDI for whom surgery is not feasible, providing that (1) surgical consultation is always sought, (2) standardized and screened FMT products are readily available, (3) the treating or consulting physicians have experience with FMT, and (4) a careful risk assessment of the benefits and risk are made on a case-by-case basis. The expert team should specifically also discuss intravenous antibiotic pre-and post-FMT treatment, dependent on the patient's underlying condition, follow-up parameters and necessary treatment with other non-CDI antibiotics.

V. What is the best treatment for recurrent CDI?

- **If the initial CDI episode was treated with vancomycin or metronidazole, then fidaxomicin 200 mg twice daily for 10 days is the preferred agent to treat a first CDI recurrence.** *Strong, Low*
- **If the initial CDI episode was treated with fidaxomicin, consider addition of bezlotoxumab (when available and feasible) to an oral SoC antibiotic treatment, i.e. vancomycin or fidaxomicin.** *Addition to vancomycin: Weak, Moderate / Addition to fidaxomicin: good practice statement*
- **Consider a vancomycin tapering and pulse scheme for recurrent CDI when fidaxomicin or or bezlotoxumab are not available or feasible.** *Weak, Very low*

Fidaxomicin and bezlotoxumab

As described under *section I 'initial CDI'*, fidaxomicin results in similar cure as vancomycin but a 10-14% lower absolute risk CDI recurrence rate [166, 167]. In a combined subset analysis (n=178) of the two RCTs, a 16% lower recurrence rate with fidaxomicin was reported in patients with a first CDI recurrence within 3 months of a prior episode [217]. However, a multicentre retrospective study (n=81) found that patients with prior CDI episodes are less likely to respond to therapy and more likely to have a recurrence [218]. Hence, use of fidaxomicin earlier in the course of (recurrent episodes of) CDI, may lead to increased benefit.

In the subgroup of patients with at least one CDI episode in the previous 6 months in the MODIFY trials, addition of bezlotoxumab also resulted in an absolute reduction in recurrence rates, 13% in MODIFY-I (n=212) and 19% in MODIFY-II (n=223), respectively. Therefore, when available and feasible, bezlotoxumab might be added to SoC anti-CDI antibiotics (vancomycin or fidaxomicin) when treating a recurrent episode of CDI [185]. It should be noted that the proportion of patients receiving fidaxomicin as SoC in the MODIFY-I and II trials was 4%, whereas the proportion receiving vancomycin was 48%.

In conclusion, prospective data on treatment of first recurrences is limited to subanalysis of RCTs and quality of evidence can therefore be graded moderate at best. It should be noted that the initial episodes were within 3 and 6 months of the recurrent episode, rather than the 2 months suggested by the ESCMID guidelines [185, 217]. The reduction of recurrences rates with fidaxomicin and bezlotoxumab seems sustained in patients with prior CDI. Regarding bezlotoxumab, the post-hoc analysis of pre-specified risk factors in the MODIFY trials indicates that the benefit of bezlotoxumab is most pronounced in patients with rCDI and who had other risk factors for CDI recurrence [186]. The committee considers fidaxomicin the agent of choice for a first CDI recurrence when the initial episode was treated with vancomycin or metronidazole, and considers SoC + bezlotoxumab when the initial episode was treated with fidaxomicin.

Vancomycin taper and pulse

When other options for treatment of a first or second recurrent CDI episode are not available, i.e. fidaxomicin, bezlotoxumab and FMT, a vancomycin taper and pulse regime may be considered. A secondary analysis of patients with recurrent CDI placebo arms of two RCTs found fewer recurrences with vancomycin taper (n=29, recurrence rate 31%), or pulse (n=7, 14%), than with vancomycin 1-2 weeks (n=83, 43-71%) [219]. The mean number of prior episodes of these patients was 3.2 [219]. A small RCT that studied patients with 4-5 prior CDI episodes found no significant difference in recurrence rates of vancomycin taper treatment arm (44%) compared with a full course of vancomycin followed by FMT (56%). The analysis included only 28 patients, because the trial was terminated for futility to demonstrate superiority of FMT [220]. The tapering scheme used in the trial was: 2 weeks of vancomycin 125 mg orally four times daily, followed by 1 week 125 mg twice daily, then 1 week 125 mg daily, then 1 week 125 mg every second day, and finally 125 mg orally every third day for 1 week.

Other strategies

Follow-on rifaximin after SoC treatment might also be effective for prevention of recurrent CDI [31, 221], however concerns for resistance development remain and some European countries showed high percentages of resistance to rifampicin (the same class of antibiotics as rifaximin) in currently circulating *C. difficile* strains [222]. In the future, non-toxigenic *C. difficile* (NTCD), bacterial spores, bacterial consortia, or other live biotherapeutic products may provide a viable strategy to prevent CDI recurrences. An interesting phase 2 trial that are actively recruiting patients is investigating ACX-362E, which is a novel DNA polymerase III inhibitor (NCT04247542).

VI. What is the best treatment for multiple recurrent CDI?

- **Treatment options for a second or further CDI recurrence include FMT after SoC antibiotic pre-treatment or bezlotoxumab in addition to SoC antibiotic treatment. The choice between either depends on patients' characteristics, previous treatment, local regulations, availability and feasibility. For FMT an adequate multidisciplinary risk assessment is mandatory and FMT products should be available with standardized preparation and screening. *Weak, Moderate (FMT) / Low (bezlotoxumab)***

Prospective data on the treatment of second or further CDI recurrences is limited. A small RCT included 24 patients in the fidaxomicin treatment arm, with a median of four prior CDI episodes [223]. Of these patients, 13 (54%) had resolution of *C. difficile* associated diarrhoea at 8 weeks. Effectiveness of fidaxomicin (200 mg BID for 10 days) seems to decrease with multiple recurrences [218]. A report on the use of bezlotoxumab in Finland revealed that bezlotoxumab was mostly used in severely immunocompromised patients with (multiple) prior CDI episodes [224]. The majority (73%) of 44 patients had not experienced a relapse at 3 months. Importantly, this study illustrates that FMT could be avoided in patients that were awaiting FMT. A report on Spanish real-world experience showed similar results: sustained cure at 12 weeks with bezlotoxumab was 75% in patients with a second or further recurrence (n=24), while sustained cure was 93% in patients with a first recurrence [225]. Likewise, in a real-world experience report from the United States, sustained cure after bezlotoxumab treatment was 79% in patients with two or more recurrences (n=120) and 90% in patients with one recurrence (n=49) ever [226].

Multiple small RCTs and prospective cohorts studied FMT in patients with (multiple) recurrent CDI with success rates ranging from 44% to 100% with one infusion, and 69% to 100% with multiple infusions [220, 223, 227-234]. It should be noted that the mode of FMT administration differs among these studies: duodenal or colonic infusion, instillation via enema, or administration via capsules. However, only three RCTs used a control group that included recommended SoC antibiotics, vancomycin or fidaxomicin [223, 227, 229]. These trials found resolution of *C. difficile* associated diarrhoea in 65%, 81% and 92% after one infusion, and $\geq 90\%$ after multiple infusions [223, 227, 229]. Results of registries both in the Netherlands and North America indicate cure rates with one FMT administration of 89% at 1-2 months [213, 235]. We cannot underestimate the importance of standardized donor screening programs and best practices [236-239] to prevent transmission of enteropathogens and multi-drug resistant pathogens, as illustrated by two Food and Drug Administration (FDA) warnings [240, 241]. FMT should preferably be performed with products from non-commercial and approved stool banks which undergo regularly independent quality assessments and also maintain a registry with appropriate follow up of donors and patients to recognize early and late complications of FMT. For standardization and screening of donor suspensions we refer to applying guidance documents [236, 239]. Nevertheless, FMT may result in transfer of (innocuous) parasites or procarcinogenic bacteria with unknown long-term effects, or transfer of unknown infectious, pathogenic or carcinogenic agents [242, 243]. In patients with inflammatory bowel disease (IBD), FMT may result in a disease flare, but this effect may be overestimated due to incomplete assessment of pre-FMT IBD activity [244]. This illustrates that the risks and benefits of FMT have to be carefully evaluated on a case-by-case basis. Ideally, candidates for FMT are carefully assessed by a multidisciplinary expert panel [245]. For the purpose of this guideline we will not discuss the various formulations, dosages and delivery routes for FMT. Efforts are undertaken to produce standardized faecal microbiota suspensions that are manufactured conforming to Good Manufacturing Practice to address regulatory issues.

The evidence supporting FMT is graded moderate: the RCTs were unblinded and small, however the outcome was consistent with a large effect size. The evidence supporting bezlotoxumab for multiple recurrent CDI is accumulating, though at this point based on retrospective analysis only. However, all reports indicate consistent sustained cure rates of 73% or higher for a second or further recurrences. Therefore evidence is upgraded from very low to low.

VII. Can prognostic factors identify patients at risk for severe CDI?

- **The most important risk factors for severe CDI are older age (>65 years old) and presence of multiple comorbidities.** *Strong, Moderate*

An important characteristic of our literature review is the selection of articles complying to predefined criteria and a strict prognostic GRADE approach (methods section, page 5). To our knowledge, this approach has not been previously used for prognostic factors for CDI. Therefore results may differ from conclusions from previous systematic reviews. In general, the evidence was limited by the mainly retrospective nature of the data and small sample sizes. Hence, the overall quality of evidence regarding prognostic factors for severe CDI in the selected articles was graded very low to moderate.

We identified *older age* [29, 32-36, 41, 43, 44, 47, 50, 54, 56-59, 61, 66, 71, 72, 74, 75, 77, 78, 81-83, 88-90, 92, 94, 97, 101, 103, 106-108, 110, 111, 113-115] and *presence of multiple comorbidities* [34-36, 41-44, 47, 57, 60, 61, 65, 67, 81, 83, 84, 89, 90, 93, 111, 113, 114] as the most important risk factors. This is supported by the fact that for these variables a dose effect was observed: the risk of severe disease was higher with increasing age or increasing number of comorbidities. We did not identify an association between a specific medical condition and severe CDI. Defining cut-off values for age and number of comorbidities is challenging since many studies used continuous values or varying cut-off values. Here, we define older age as >65years old, as the majority of studies reported a higher risk for severe infection in patients aged over 65-70 years when compared to younger patients [29, 32-34, 50, 54, 56, 59, 61, 66, 72, 74, 75, 81, 88, 89, 92, 94, 101, 107, 108, 110, 115]. Due to the heterogeneity of studies reporting on comorbidities as a risk factor, we cannot define an exact number of comorbidities required to predict a severe course of CDI. The use of PPIs, H2 receptor antagonists and antibiotics did not appear to influence the risk of severe CDI, nor did the presence of *C. difficile* strains capable to produce binary toxin [32, 34, 36, 38, 39, 42, 44, 52, 54, 57-60, 67, 68, 71, 72, 74, 77-79, 81, 83, 84, 87-90, 94, 97, 103, 108, 111, 113-116, 118]. We observed a high level of inconsistency in the results of studies assessing infection with the *C difficile* NAP1/027 strain as a risk factor. The results of the literature review and GRADING are discussed in more detail at medRxiv <https://doi.org/10.1101/2021.06.22.21259313>. In the current guideline the distinction between mild and severe CDI currently has no consequences for choice of treatment (now that metronidazole is no longer recommended as first-line treatment). Therefore, the prediction of severe CDI is less relevant at this moment. However, new therapies and studies may lead to different insights in the future. We aimed to provide a complete and clear overview of available data on risk factors for severe CDI based on a systematic search and grading, which can be used and built upon in future guidelines.

VIII. Can prognostic factors identify patients at risk for recurrent CDI?

- **Older age (>65years old) is the most important risk factor for recurrent CDI.** *Strong, Moderate*
- **Patients with prior CDI episode(s) are at an increased risk for recurrent CDI.** *Strong, Moderate*
- **Patients with healthcare-associated CDI and prior hospitalization in the last three months are considered at increased risk for recurrent CDI.** *Weak, Low*
- **Patients with concomitant non-CDI antibiotic use after the diagnosis of CDI are considered at increased risk for recurrence of CDI.** *Weak, Very low*
- **Patients on PPI therapy are considered at increased risk for recurrent CDI.** *Weak, Very low*

As mentioned in the previous paragraph, an important characteristic (albeit limitation or strength) of our analysis is the selection of articles complying to predefined criteria and a strict GRADE approach. We found that the overall quality of evidence for the prognosis of recurrent CDI was low to moderate. Most of the studies were retrospective, with a high to moderate risk of bias. A complete overview and discussion of all risk factors studied is provided at **medRxiv** <https://doi.org/10.1101/2021.06.22.21259313>.

Older age was the only risk factor for which we found a moderate to large effect size and a dose dependent effect [25, 106, 108, 119, 120, 122-125, 127, 129-135, 137-142, 144-155]. In line with the prognostic factors for severe CDI we define older age as >65years old.

Patients with *healthcare-associated CDI* have a higher risk of recurrence than patients with community-acquired CDI [108, 122, 123, 127, 142, 145, 146, 151-153]. This is supported by the association of prior hospitalization (within 3 months) and CDI recurrence [122, 127, 131, 133, 139, 144, 147, 152].

In the 23 included studies that investigated *Proton pump inhibitor (PPI)* use, univariate analysis did not show a clear association with rCDI, while on multivariate analyses there appeared to be an association [106, 119, 120, 123, 129, 130, 132, 133, 135, 136, 138, 140, 142, 146, 147, 149-155, 157]. Bias may have arisen here as most studies did not include PPIs in multivariate analyses when there

was no significant association in univariate analysis. Several meta-analyses suggest that PPI use is a risk factor for rCDI [246-249].

The data on *prior CDI episodes* as a risk factor was inconsistent [108, 122-124, 131, 133, 141, 146], though the two prospective studies of higher quality found a clear association between previous recurrence and a subsequent CDI episode on multivariate analysis [108, 141]. Furthermore, data of the pivotal trials on fidaxomicin and bezlotoxumab show higher recurrences rates in patients with a previous CDI episode [166, 167, 185, 186, 250]. Consequently, we have upgraded the level of evidence from low to moderate.

Data on *concomitant non-CDI antibiotic use* was also conflicting [120, 128, 134, 137, 142, 146, 148, 150]. A high quality prospective study points towards no significant association in both uni- and multivariate analysis [137]. However, several case-control studies have identified antibiotic use as an important risk factor for CDI, most notably fluoroquinolones, cephalosporins, carbapenems and clindamycin use [251-256]. Overall, we consider patients with concomitant non-CDI antibiotic use at increased risk for recurrent CDI.

We found insufficient evidence to consider severe CDI [120, 123, 125, 130, 135, 141-143, 149, 153], and presence of comorbidities as risk factors for recurrent CDI [25, 60, 108, 119, 120, 122, 123, 125, 127, 129-135, 137, 139-156]. Severe CDI and immunocompromised status were prespecified risk factors for CDI recurrence in the MODIFY trials, although in the placebo arms the CDI recurrence rate was lower in the severe CDI subgroup (28/125, 22%) and similar in the immunocompromised subgroup (42/153, 27.28%), when compared to the overall placebo arm (26/773, 27%) [185]. The *C. difficile* ribotype 027 strain was not evidently associated with CDI recurrence [108, 120, 128, 146, 150]. Of note, in the placebo arms of the MODIFY trials the recurrence rate for patients with ribotypes 027/078/244 was 41%. We did not find changes in white blood cell count, albumin, creatinine and C-reactive protein levels at the time of admission to be clear prognostic markers for recurrent CDI [108, 124, 131, 134, 135, 142, 145-149, 151, 152].

IX. Is there a place for prophylaxis for prevention of CDI?

- **Routine administration of probiotics to prevent CDI when on antibiotic treatment is not recommended.** *Strong , low*

- **Routine prophylaxis with anti-CDI antibiotics when on systemic antibiotic treatment is not recommended.** *Good practice statement*
- **In very selected patients with a history of multiple recurrent CDI precipitated by systemic antibiotic use, prophylaxis with microbiota sparing anti-CDI antibiotics may be warranted, after carefully balancing the risk and benefits, and after consultation with an Infectious Diseases or Clinical Microbiology specialist.** *Good practice statement*

Prophylaxis with probiotics

The previous ESCMID guideline concluded that there was insufficient evidence to support administration of probiotics, toxin-binding resins and polymers or monoclonal antibodies for the treatment of non-severe disease [1]. An updated Cochrane review on the use of probiotics for prevention of CDI found that probiotics are effective in trials with a *C. difficile* associated diarrhea baseline risk of >5% (NNTB = 12; moderate certainty evidence) [257]. We consider such a high incidence not representative of clinical practice; the PLACIDE trial for example found occurrence of CDI to be around 1% in patients ≥ 65 years with i.v. antibiotics. Further, the trials that were included in the Cochrane meta-analysis used different probiotic formulations which complicates interpretation of the results. For example, a recent retrospective cohort study (n=8763) found that coadministration of *S. boulardii* led to a reduced risk of hospital onset CDI; OR 0.57 with a CDI incidence of 0.66% [258]. In contrast, the results of a large RCT, the PLACIDE trial (n=2941) found no effect of lactobacilli and bifidobacteria formulation on incidence of CDI [259]. Probiotics may actually delay microbiome reconstitution after antibiotic treatment [260], and concerns about adverse effects remain as illustrated by increased mortality in a pancreatitis trial [261].

Prophylaxis with CDI antibiotics

The use of CDI antibiotics for primary prevention of CDI has not been discussed in previous ESCMID and IDSA guidelines [1, 3]. However, several recent retrospective observational studies have been published that reported a 5% to 30% reduction in CDI occurrence with oral vancomycin prophylaxis in patients receiving broad-spectrum antibiotics [257, 262-268]. These studies in general focused on patients considered at risk for CDI, such as haematological patients, patients with a prior CDI episode, stem cell transplant patients, or solid organ transplant patients. An open label RCT (n=100) with a follow-up of 3 months found a benefit of oral vancomycin prophylaxis vs. no prophylaxis (CDI occurrence 0% vs 16%) in patients aged 60 years or older who received systemic antibiotics and who had prior hospitalization with systemic antibiotic therapy in the previous month [269]. It should be noted that the CDI incidence of 16% in the placebo group was rather high. A placebo controlled RCT

in patients undergoing stem cell transplantation with planned fluoroquinolone prophylaxis found no difference between fidaxomicin prophylaxis and placebo in the composite end-point of prophylaxis failure (confirmed CDI, receiving CDI active medication, missing CDI assessment) [270]. However, follow-up was limited to 30 days and a sensitivity analysis found a 6.4% reduction (95%CI 2.2 to 10.6) in CDI occurrence with fidaxomicin prophylaxis. We acknowledge the potential benefit of prophylaxis in selected patients, but are cautious with wide-spread application because of potential side-effects, microbiome distortion, the potential for development or acquisition of antimicrobial resistance and an associated increased risk for recurrent CDI [271, 272]. Some studies on vancomycin prophylaxis have attempted to assess the risk for VRE colonization [266, 268, 269, 273, 274]. However, these assessments are hampered by short follow-up, unclear microbiological methods or a focus on VRE infection rather than colonization. Therefore, concerns regarding resistance selection and development remain. Overall, the committee does not support routine prophylaxis with CDI antibiotics when on systemic antibiotic treatment. However, we feel that in very selected patients with a history or multiple recurrent CDI incited by systemic antibiotic use, prophylaxis with microbiota sparing CDI antibiotics may be warranted, after carefully balancing the risk and benefits, and after consultation with an Infectious Diseases or Clinical Microbiology specialist.

Alternative preventive strategies

A novel approach for primary prevention of CDI is co-administration of a poorly absorbed beta-lactamase (ribaxamase, SYN004) when administering broad-spectrum antibiotics [275]. A phase 2b trial (n=412) found a 2.4% risk reduction for CDI occurrence when co-administering ribaxamase with ceftriaxone, although the lower boundary of the 95% CI crossed the border of no effect (-0.6). Clinical development of ribaxamase is ongoing. Another approach for primary prevention might be active immunisation. Although preclinical studies have been promising, a phase 3 *C. difficile* toxoid vaccine trial was terminated because of futility and clinical development of this vaccine candidate was stopped [276].

Other considerations

The role of probiotics and ancillary treatment strategies such as FMT and bezlotoxumab have been discussed above. We did not identify new trials on the use of intravenous immunoglobulins (IVIG) that allow for recommendations on the use of IVIG.

Regarding optimal CDI therapy during pregnancy there remains a paucity of data. Pregnant or breast-feeding women are typically excluded from pivotal trials. A post-market study on fidaxomicin

in patients with a medical condition of specific interest did not include pregnant women [195]. Fidaxomicin, oral vancomycin and metronidazole were originally classified as pregnancy category B by the FDA (no evidence in risk studies), whereas i.v. vancomycin hydrochloride was designated category C (risk cannot be ruled out) [277-280]. It should be noted the pregnancy labelling scheme has recently been revised by the FDA from alphabetical to descriptive. Importantly, some pre-constituted i.v. formulation of vancomycin contain the excipients PEG 400 and NADA and therefore cannot be used for oral administration in pregnant woman, as these have caused foetal malformations in animal reproductive studies [281]. Vancomycin use (i.v) in the 2nd and 3rd trimester (n=10) did not result in foetal nephrotoxicity or sensorineural hearing loss at 3 months [282]. Perinatal i.v. vancomycin prophylaxis did not result in sensorineural hearing loss of the new-born, or any major adverse events in mothers (n=55) and new-borns [282]. Vancomycin crosses the placenta, but oral vancomycin is minimally absorbed from the gastro-intestinal tract, although measurable serum levels may occur [45]. Therefore, it is reasonable to use vancomycin oral tablets during pregnancy. Therapeutic drug monitoring may be considered. During pregnancy, prolonged administration and high dosing of vancomycin should be discouraged as this is a proposed risk factors for measurable serum concentrations [45]. Fidaxomicin is also poorly absorbed from the gastro-intestinal tract and resulted in serum levels around the limit of detection (5 ng/mL) in a phase-1 study with healthy volunteers [283]. No foetal harm was found in reproduction studies in rats and rabbits [277]. Bezlotoxumab has not been investigated in pregnant woman or animal reproductive and developmental studies. In the absence of clinical data and experience with fidaxomicin, we prefer vancomycin during pregnancy. Fidaxomicin may be used after carefully balancing the risks and benefits.

The timing of the start of empirical treatment was not included in our PICO search. The 2017 IDSA guideline advised to start empiric treatment only when a significant delay in laboratory confirmation is expected or when dealing with fulminant CDI (weak recommendation) [3]. We concur with the suggested approach and strongly discourage the start of empirical therapy without diagnostic testing in other cases. In the absence of evidence and based on clinical experience, we also discourage treatment beyond the recommended standard duration of 10-14 days with SoC antibiotics because of lack of response or co-administered antibiotic treatment.

We have retrieved several cost-effectiveness studies. These studies found that different treatments were (most) cost-effective: vancomycin [284], fidaxomicin [173-180], bezlotoxumab [175, 188, 189], and FMT [285-287] have all been described as cost-effective. Decreased recurrence rate and subsequent costs of re-hospitalisation and complications may result in cost-effectiveness depending on the willingness-to-pay threshold per gained quality-adjusted life-year. Importantly, many cost-

effectiveness studies are co-authored or funded by employees of pharmaceutical companies [176-180, 188, 189]. However, selection of CDI treatments based on cost-benefit analysis of health-economic studies is beyond the scope of this guideline and will remain an interesting next project, though it is probably better to perform these studies on a national level.

Formulating guideline recommendations, especially for a multinational ESCMID guideline is challenging, considering differences in regulations, availability and reimbursements of treatments. On the one hand one should advise the best treatment available, but on the other hand a guideline that recommends agents that the majority of physicians will not prescribe due to economic restraints is useless. We acknowledge that each country or local institution should adapt the guideline to its local economic situation. With this guideline, we have aimed to make evidence-based recommendations for the best treatments available and offer alternatives when the treatment of first choice might not be available or feasible due to economic restraints, or when access to the preferred agent is limited..

Research gaps

While drafting this guideline and appraising the evidence for the optimal treatment of CDI we identified several key topics that deserve further attention and will be of great interest for future treatment algorithms. The most important topics for future research are:

1. Assessing the optimal treatment in severe-complicated and refractory CDI.
2. Comparing the effectiveness of bezlotoxumab and FMT for the treatment of multiple recurrent CDI.
3. Assessing the benefit of adding bezlotoxumab to fidaxomicin treatment.
4. Discontinue therapy with the inciting antimicrobial agent in non-severe CDI as a single intervention.
5. Investigation into optimal CDI treatment and treatment algorithms in large scale trials independent from pharmaceutical industry (i.e. not as sponsor or subsidising party).
6. Optimal identification of patients at risk for recurrent CDI. These patients might be offered adjuvant bezlotoxumab or FMT earlier in the course of disease.
7. Insight into the exact mechanism of FMT for CDI treatment. This might enable a more regulated and standardized preparation process of FMT products.

8. Insight into the benefit of FMT and bezlotoxumab in specific populations such as patients with Inflammatory Bowel Disease (IBD) and the immunocompromised hosts.
9. Assessment of other adjunctive treatments such as NTCD and follow-on rifaximin.
10. Effectiveness of microbial consortia and spore formulations that are under development
11. Selection of CDI treatments based on independent cost-benefit analysis of health-economic studies in different settings and populations, e.g. the general CDI population, patients with IBD, the hospitalized versus non-hospitalized patient, and the immunocompromised host.

Acknowledgements

The authors would like to thank J.W. Schoones, WALEUS Library, Leiden University Medical Centre, Leiden, the Netherlands, for his assistance in constructing a search of literature. Also, we would like to thank professor Olaf Dekkers, Department of Internal Medicine & Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands, for his advice on methodology. This guideline was granted full ESCMID endorsement after a public consultation procedure; we thank Anita Novak, Guido Granata, Remi Le Guern, Michael Perry, Luc Bergeron, Vivienne Weston, Martin Cormican, Nicola Petrosillo, Virginie Prendki, Peter Velikov and Andrew Morris, Javier Cobo, Maddalena Gianella and the ESCMID guidelines subcommittee for critical review of the draft guideline. Finally we wish to thank the following external experts for their comments: Stuart Johnson, Vivian Loo, Thomas Riley, Giovanni Cammarota, Josbert Kelle, Andreas Sturm and Nancy C. Caralla.

Funded

This guideline was funded by the ESCMID

Transparency declaration

All members of the drafting group submitted a COI form to the ESCMID guidelines manager.

REFERENCES

1. Debast, S.B., et al., *European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection*. Clin Microbiol Infect, 2014. **20 Suppl 2**: p. 1-26.
2. Ooijevaar, R.E., et al., *Update of treatment algorithms for Clostridium difficile infection*. Clin Microbiol Infect, 2018. **24**(5): p. 452-462.
3. McDonald, L.C., et al., *Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)*. Clin Infect Dis, 2018. **66**(7): p. 987-994.
4. Crobach, M.J., et al., *European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection*. Clin Microbiol Infect, 2016. **22 Suppl 4**: p. S63-81.
5. Tschudin-Sutter, S., et al., *Guidance document for prevention of Clostridium difficile infection in acute healthcare settings*. Clin Microbiol Infect, 2018. **24**(10): p. 1051-1054.
6. Higgins, J.P., et al., *The Cochrane Collaboration's tool for assessing risk of bias in randomised trials*. BMJ, 2011. **343**: p. d5928.
7. Hayden, J.A., et al., *Assessing bias in studies of prognostic factors*. Ann Intern Med, 2013. **158**(4): p. 280-6.
8. Guyatt, G.H., et al., *Going from evidence to recommendations*. BMJ, 2008. **336**(7652): p. 1049-51.
9. Huguet, A., et al., *Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework*. Syst Rev, 2013. **2**: p. 71.
10. Brouwers, M.C., et al., *AGREE II: advancing guideline development, reporting and evaluation in health care*. CMAJ, 2010. **182**(18): p. E839-42.
11. Senchyna, F., et al., *Clostridium difficile PCR Cycle Threshold Predicts Free Toxin*. J Clin Microbiol, 2017. **55**(9): p. 2651-2660.
12. Crobach, M.J.T., et al., *Nucleic Acid Amplification Test Quantitation as Predictor of Toxin Presence in Clostridium difficile Infection*. J Clin Microbiol, 2018. **56**(3).
13. Cohen, S.H., et al., *Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)*. Infect Control Hosp Epidemiol, 2010. **31**(5): p. 431-55.
14. Kuijper, E.J., et al., *Emergence of Clostridium difficile-associated disease in North America and Europe*. Clin Microbiol Infect, 2006. **12 Suppl 6**: p. 2-18.
15. Knoop, F.C., M. Owens, and I.C. Crocker, *Clostridium difficile: clinical disease and diagnosis*. Clin Microbiol Rev, 1993. **6**(3): p. 251-65.
16. Krutova, M., M.H. Wilcox, and E.J. Kuijper, *The pitfalls of laboratory diagnostics of Clostridium difficile infection*. Clin Microbiol Infect, 2018. **24**(7): p. 682-683.
17. Lewis, S.J. and K.W. Heaton, *Stool form scale as a useful guide to intestinal transit time*. Scand J Gastroenterol, 1997. **32**(9): p. 920-4.
18. Al-Nassir, W.N., et al., *Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin*. Clin Infect Dis, 2008. **47**(1): p. 56-62.

19. Kuijper, E.J. and M.H. Wilcox, *Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection?* Clin Infect Dis, 2008. **47**(1): p. 63-5.
20. Wilcox, M.H. and R. Howe, *Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin.* J Antimicrob Chemother, 1995. **36**(4): p. 673-9.
21. Louie, T.J., et al., *Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea.* Clin Infect Dis, 2006. **43**(4): p. 411-20.
22. Surawicz, C.M., et al., *Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections.* Am J Gastroenterol, 2013. **108**(4): p. 478-98; quiz 499.
23. Moudgal, V. and J.D. Sobel, *Clostridium difficile colitis: a review.* Hosp Pract (1995), 2012. **40**(1): p. 139-48.
24. Kelly, C.P., *Can we identify patients at high risk of recurrent Clostridium difficile infection?* Clin Microbiol Infect, 2012. **18 Suppl 6**: p. 21-7.
25. Fekety, R., et al., *Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial.* Clin Infect Dis, 1997. **24**(3): p. 324-33.
26. Pepin, J., et al., *Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada.* Clin Infect Dis, 2006. **42**(6): p. 758-64.
27. Figueroa, I., et al., *Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.* Clin Infect Dis, 2012. **55 Suppl 2**: p. S104-9.
28. Bauer, M.P., et al., *European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI).* Clin Microbiol Infect, 2009. **15**(12): p. 1067-79.
29. Sailhamer, E.A., et al., *Fulminant Clostridium difficile colitis: patterns of care and predictors of mortality.* Arch Surg, 2009. **144**(5): p. 433-9; discussion 439-40.
30. Bateman, B.T., et al., *Adjuvant vancomycin for antibiotic prophylaxis and risk of Clostridium difficile infection after coronary artery bypass graft surgery.* J Thorac Cardiovasc Surg, 2013. **146**(2): p. 472-8.
31. Garey, K.W., et al., *A randomized, double-blind, placebo-controlled pilot study to assess the ability of rifaximin to prevent recurrent diarrhoea in patients with Clostridium difficile infection.* J Antimicrob Chemother, 2011. **66**(12): p. 2850-5.
32. Alicino, C., et al., *Increasing incidence of Clostridium difficile infections: results from a 5-year retrospective study in a large teaching hospital in the Italian region with the oldest population.* Epidemiol Infect, 2016. **144**(12): p. 2517-26.
33. Ananthakrishnan, A.N., et al., *Predictors of severe outcomes associated with Clostridium difficile infection in patients with inflammatory bowel disease.* Aliment Pharmacol Ther, 2012. **35**(7): p. 789-95.
34. Andrews, C.N., et al., *Clostridium difficile-associated diarrhea: predictors of severity in patients presenting to the emergency department.* Can J Gastroenterol, 2003. **17**(6): p. 369-73.
35. Archbald-Pannone, L.R., et al., *Delirium and other clinical factors with Clostridium difficile infection that predict mortality in hospitalized patients.* Am J Infect Control, 2015. **43**(7): p. 690-3.

36. Atamna, A., et al., *The effect of statins on the outcome of Clostridium difficile infection in hospitalized patients*. European Journal of Clinical Microbiology and Infectious Diseases, 2016. **35**(5): p. 779-784.
37. Barker, A.K., et al., *Tobacco use as a screener for Clostridium difficile infection outcomes*. J Hosp Infect, 2018. **98**(1): p. 36-39.
38. Bauer, K.A., et al., *Impact of the NAP-1 strain on disease severity, mortality, and recurrence of healthcare-associated Clostridium difficile infection*. Anaerobe, 2017. **48**: p. 1-6.
39. Berry, C.E., et al., *Is there a relationship between the presence of the binary toxin genes in Clostridium difficile strains and the severity of C. difficile infection (CDI)?* Eur J Clin Microbiol Infect Dis, 2017. **36**(12): p. 2405-2415.
40. Bhangu, S., et al., *Mortality and risk stratification in patients with Clostridium difficile-associated diarrhoea*. Colorectal Dis, 2010. **12**(3): p. 241-6.
41. Boone, J.H., et al., *Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality*. Eur J Clin Microbiol Infect Dis, 2014. **33**(6): p. 1045-51.
42. Caupenne, A., et al., *Acute Clostridioides difficile Infection in Hospitalized Persons Aged 75 and Older: 30-Day Prognosis and Risk Factors for Mortality*. J Am Med Dir Assoc, 2019.
43. Charilaou, P., et al., *Acute kidney injury impact on inpatient mortality in Clostridium difficile infection: A national propensity-matched study*. J Gastroenterol Hepatol, 2018. **33**(6): p. 1227-1233.
44. Chintanaboina, J., et al., *Predictors of 30-Day Mortality in Hospitalized Patients with Clostridium difficile Infection*. Southern Medical Journal, 2017. **110**(8): p. 546-549.
45. Clohessy, P., J. Merif, and J.J. Post, *Severity and frequency of community-onset Clostridium difficile infection on an Australian tertiary referral hospital campus*. International Journal of Infectious Diseases, 2014. **29**: p. 152-155.
46. Cohen, N.A., et al., *Clostridium difficile fecal toxin level is associated with disease severity and prognosis*. United European Gastroenterol J, 2018. **6**(5): p. 773-780.
47. Das, R., P. Feuerstadt, and L.J. Brandt, *Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difficile-associated disease*. Am J Gastroenterol, 2010. **105**(9): p. 2040-9.
48. De Francesco, M.A., et al., *Correlation between tcdB gene PCR cycle threshold and severe Clostridium difficile disease*. Anaerobe, 2019. **59**: p. 141-144.
49. Dudukgian, H., et al., *C. difficile colitis--predictors of fatal outcome*. J Gastrointest Surg, 2010. **14**(2): p. 315-22.
50. Figh, M.L., et al., *External Validation of Velazquez-Gomez Severity Score Index and ATLAS Scores and the Identification of Risk Factors Associated with Mortality in Clostridium difficile Infections*. Am Surg, 2017. **83**(12): p. 1347-1351.
51. Fountain, E.M., et al., *Thrombocytopenia in hospitalized patients with severe clostridium difficile infection*. J Thromb Thrombolysis, 2017. **43**(1): p. 38-42.
52. Fujii, L., et al., *Appendectomy and risk of clostridium difficile recurrence*. Infectious Diseases in Clinical Practice, 2013. **21**(1): p. 28-32.
53. Hanania, A., et al., *Fecal calprotectin in the diagnosis of clostridium difficile infection*. Infectious Diseases in Clinical Practice, 2016. **24**(1): p. 31-34.
54. Henrich, T.J., et al., *Clinical risk factors for severe Clostridium difficile-associated disease*. Emerg Infect Dis, 2009. **15**(3): p. 415-22.

55. Hubert, B., et al., *A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec*. Clin Infect Dis, 2007. **44**(2): p. 238-44.
56. Huttunen, R., et al., *Case fatality associated with a hypervirulent strain in patients with culture-positive Clostridium difficile infection: a retrospective population-based study*. Int J Infect Dis, 2012. **16**(7): p. e532-5.
57. Kassam, Z., et al., *Clostridium difficile associated risk of death score (CARDS): a novel severity score to predict mortality among hospitalised patients with C. difficile infection*. Aliment Pharmacol Ther, 2016. **43**(6): p. 725-33.
58. Kenneally, C., et al., *Analysis of 30-day mortality for clostridium difficile-associated disease in the ICU setting*. Chest, 2007. **132**(2): p. 418-24.
59. Khanafer, N., et al., *Factors predictive of severe Clostridium difficile infection depend on the definition used*. Anaerobe, 2016. **37**: p. 43-8.
60. Khanna, S., et al., *The epidemiology of community-acquired Clostridium difficile infection: a population-based study*. Am J Gastroenterol, 2012. **107**(1): p. 89-95.
61. Khanna, S., et al., *Epidemiology, outcomes, and predictors of mortality in hospitalized adults with Clostridium difficile infection*. Intern Emerg Med, 2016. **11**(5): p. 657-65.
62. Khanna, S., et al., *Acute kidney injury is an independent marker of severity in Clostridium difficile infection: a nationwide survey*. J Clin Gastroenterol, 2013. **47**(6): p. 481-4.
63. Kim, J., et al., *Fecal Calprotectin Level Reflects the Severity of Clostridium difficile Infection*. Ann Lab Med, 2017. **37**(1): p. 53-57.
64. Kim, J., Y. Kim, and H. Pai, *Clinical Characteristics and Treatment Outcomes of Clostridium difficile Infections by PCR Ribotype 017 and 018 Strains*. PLoS One, 2016. **11**(12): p. e0168849.
65. Kulaylat, A.S., et al., *Development and Validation of a Prediction Model for Mortality and Adverse Outcomes Among Patients With Peripheral Eosinopenia on Admission for Clostridium difficile Infection*. JAMA Surg, 2018. **153**(12): p. 1127-1133.
66. Lee, H.C., et al., *Clinical Outcomes in Hospitalized Patients with Clostridium difficile Infection by Age Group*. Korean J Gastroenterol, 2016. **67**(2): p. 81-6.
67. Leibovici-Weissman, Y., et al., *Risk factors for short- and long-term mortality in very old patients with Clostridium difficile infection: A retrospective study*. Geriatr Gerontol Int, 2017. **17**(10): p. 1378-1383.
68. Lungulescu, O.A., et al., *CSI: a severity index for Clostridium difficile infection at the time of admission*. J Hosp Infect, 2011. **79**(2): p. 151-4.
69. Mascart, G., et al., *Impact of ribotype 027 on Clostridium difficile infection in a geriatric department*. Eur J Clin Microbiol Infect Dis, 2013. **32**(9): p. 1177-82.
70. Miller, M., et al., *Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality*. Clin Infect Dis, 2010. **50**(2): p. 194-201.
71. Morrison, R.H., et al., *Risk factors associated with complications and mortality in patients with Clostridium difficile infection*. Clin Infect Dis, 2011. **53**(12): p. 1173-8.
72. Na, X., et al., *A Multi-Center Prospective Derivation and Validation of a Clinical Prediction Tool for Severe Clostridium difficile Infection*. PLoS One, 2015. **10**(4): p. e0123405.

73. Ogielska, M., et al., *Emergence of community-acquired Clostridium difficile infection: the experience of a French hospital and review of the literature*. Int J Infect Dis, 2015. **37**: p. 36-41.
74. Patel, U.C., J.T. Wieczorkiewicz, and J. Tuazon, *Evaluation of advanced age as a risk factor for severe Clostridium difficile infection*. Journal of Clinical Gerontology and Geriatrics, 2016. **7**(1): p. 12-16.
75. Pepin, J., et al., *Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity*. Cmaj, 2004. **171**(5): p. 466-72.
76. Polivkova, S., et al., *Clostridium difficile ribotype 176 - A predictor for high mortality and risk of nosocomial spread?* Anaerobe, 2016. **40**: p. 35-40.
77. Rao, K., et al., *Poor functional status as a risk factor for severe Clostridium difficile infection in hospitalized older adults*. J Am Geriatr Soc, 2013. **61**(10): p. 1738-42.
78. Rao, K., et al., *Clostridium difficile ribotype 027: relationship to age, detectability of toxins A or B in stool with rapid testing, severe infection, and mortality*. Clin Infect Dis, 2015. **61**(2): p. 233-41.
79. Reigadas, E., et al., *Role of binary toxin in the outcome of Clostridium difficile infection in a non-027 ribotype setting*. Epidemiol Infect, 2016. **144**(2): p. 268-73.
80. Scardina, T., et al., *Clostridium difficile infection (CDI) severity and outcome among patients infected with the NAP1/BI/027 strain in a non-epidemic setting*. Infect Control Hosp Epidemiol, 2015. **36**(3): p. 280-6.
81. See, I., et al., *NAP1 strain type predicts outcomes from Clostridium difficile infection*. Clin Infect Dis, 2014. **58**(10): p. 1394-400.
82. Serafino, S., et al., *Clinical outcomes of Clostridium difficile infection according to strain type. A prospective study in medical wards*. Eur J Intern Med, 2018. **54**: p. 21-26.
83. Shivashankar, R., et al., *Clinical factors associated with development of severe-complicated Clostridium difficile infection*. Clin Gastroenterol Hepatol, 2013. **11**(11): p. 1466-71.
84. Starzengruber, P., et al., *Severe Clostridium difficile infection: incidence and risk factors at a tertiary care university hospital in Vienna, Austria*. Wien Klin Wochenschr, 2014. **126**(13-14): p. 427-30.
85. Tamez-Torres, K.M., et al., *Impact of Clostridium difficile infection caused by the NAP1/RT027 strain on severity and recurrence during an outbreak and transition to endemicity in a Mexican tertiary care center*. Int J Infect Dis, 2017. **65**: p. 44-49.
86. Taori, S.K., et al., *A prospective study of community-associated Clostridium difficile infections: the role of antibiotics and co-infections*. J Infect, 2014. **69**(2): p. 134-44.
87. Tschudin-Sutter, S., et al., *Growth Patterns of Clostridium difficile - Correlations with Strains, Binary Toxin and Disease Severity: A Prospective Cohort Study*. PLoS One, 2016. **11**(9): p. e0161711.
88. van der Wilden, G.M., et al., *Fulminant Clostridium difficile colitis: prospective development of a risk scoring system*. J Trauma Acute Care Surg, 2014. **76**(2): p. 424-30.
89. Vojtilova, L., et al., *Epidemiological factors influencing the development of relapsing and severe Clostridium difficile infection*. Epidemiol Mikrobiol Imunol, 2014. **63**(1): p. 27-35.
90. Walk, S.T., et al., *Clostridium difficile Ribotype Does Not Predict Severe Infection*. Clinical Infectious Diseases, 2012. **55**(12): p. 1661-1668.

91. Walker, A.S., et al., *Relationship between bacterial strain type, host biomarkers, and mortality in Clostridium difficile infection*. Clin Infect Dis, 2013. **56**(11): p. 1589-600.
92. Welfare, M.R., et al., *Co-morbidities as predictors of mortality in Clostridium difficile infection and derivation of the ARC predictive score*. J Hosp Infect, 2011. **79**(4): p. 359-63.
93. Wilson, V., et al., *Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom*. Clin Infect Dis, 2010. **50**(12): p. e77-81.
94. Xu, Q., et al., *Hospital-acquired Clostridium difficile infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university hospital*. Sci Rep, 2017. **7**(1): p. 9645.
95. Yong, F.A., et al., *Appendectomy: a risk factor for colectomy in patients with Clostridium difficile*. Am J Surg, 2015. **209**(3): p. 532-5.
96. Miller, R., et al., *Predictors of Clostridioides difficile Infection-Related Complications and Treatment Patterns among Nucleic Acid Amplification Test-Positive/Toxin Enzyme Immunoassay-Negative Patients*. J Clin Microbiol, 2020. **58**(3).
97. Menon, A., et al., *Changes in the Association between Diagnostic Testing Method, PCR Ribotype, and Clinical Outcomes from Clostridioides difficile Infection: One Institution's Experience*. Clin Infect Dis, 2020.
98. Korać, M., et al., *Clostridioides difficile ribotype distribution in a large teaching hospital in Serbia*. Gut Pathog, 2020. **12**: p. 26.
99. Essrani, R., et al., *The Impact of Appendectomy in Clostridium difficile Infection and Length of Hospital Stay*. Cureus, 2020. **12**(9): p. e10342.
100. Choi, B., et al., *Real-time polymerase chain reaction (PCR) cycle threshold and Clostridioides difficile infection outcomes*. Infect Control Hosp Epidemiol, 2021: p. 1-7.
101. Avni, T., et al., *The significance of acute kidney injury in Clostridioides difficile infection*. International Journal of Clinical Practice, 2021. **75**(3).
102. Mendez-Bailon, M., et al., *Heart Failure Is a Risk Factor for Suffering and Dying of Clostridium difficile Infection. Results of a 15-Year Nationwide Study in Spain*. J Clin Med, 2020. **9**(3).
103. Chiang, H.Y., et al., *Risk prediction for 30-day mortality among patients with Clostridium difficile infections: a retrospective cohort study*. Antimicrob Resist Infect Control, 2019. **8**: p. 175.
104. Vata, A., et al., *CLOSTRIDIUM DIFFICILE INFECTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. THE EXPERIENCE OF AN INFECTIOUS DISEASES HOSPITAL FROM NORTH-EASTERN ROMANIA*. Medical-Surgical Journal-Revista Medico-Chirurgicala, 2019. **123**(3): p. 506-512.
105. Mani, N.S., et al., *Risk Factors for BI/NAP1/027 Clostridioides difficile Infections and Clinical Outcomes Compared With Non-NAP1 Strains*. Open Forum Infectious Diseases, 2019. **6**(12): p. 4.
106. Khanna, S., et al., *Gastric acid suppression and outcomes in Clostridium difficile infection: a population-based study*. Mayo Clin Proc, 2012. **87**(7): p. 636-42.
107. Planche, T.D., et al., *Differences in outcome according to Clostridium difficile testing method: a prospective multicentre diagnostic validation study of C difficile infection*. Lancet Infect Dis, 2013. **13**(11): p. 936-45.

108. Bauer, M.P., et al., *Clostridium difficile* infection in Europe: a hospital-based survey. Lancet, 2011. **377**(9759): p. 63-73.
109. Argamany, J.R., et al., A possible association between statin use and improved *Clostridioides difficile* infection mortality in veterans. PLoS One, 2019. **14**(5): p. e0217423.
110. Leal, J., et al., Predictors of mortality and length of stay in patients with hospital-acquired *Clostridioides difficile* infection: a population-based study in Alberta, Canada. J Hosp Infect, 2019. **103**(1): p. 85-91.
111. Nagayoshi, Y., et al., Clinical significance of a positive *Clostridioides difficile* glutamate dehydrogenase test on the outcomes of hospitalized older patients. Geriatr Gerontol Int, 2020. **20**(12): p. 1138-1144.
112. Patel, H., et al., Nonsteroidal Anti-Inflammatory Drugs Impact on the Outcomes of Hospitalized Patients with *Clostridium difficile* Infection. Clin Exp Gastroenterol, 2019. **12**: p. 449-456.
113. Tay, H.L., et al., Risk factors and treatment outcomes of severe *Clostridioides difficile* infection in Singapore. Sci Rep, 2019. **9**(1): p. 13440.
114. Origuen, J., et al., Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in *Clostridium difficile* Infection: a Retrospective Cohort Study. J Clin Microbiol, 2019. **57**(2).
115. Milenkovic, B., et al., Outcomes of *Clostridioides difficile* infection in adult cancer and non-cancer patients hospitalised in a tertiary hospital: a prospective cohort study. Eur J Hosp Pharm, 2021.
116. Lopez-Cardenas, S., et al., The prognostic value of toxin B and binary toxin in *Clostridioides difficile* infection. Gut Microbes, 2021: p. 1-8.
117. Enoch, D.A., et al., Risk of complications and mortality following recurrent and non-recurrent *Clostridioides difficile* infection: a retrospective observational database study in England. J Hosp Infect, 2020. **106**(4): p. 793-803.
118. Carlson, T.J., et al., Eosinopenia and Binary Toxin Increase Mortality in Hospitalized Patients With *Clostridioides difficile* Infection. Open Forum Infect Dis, 2020. **7**(1): p. ofz552.
119. Abdelfatah, M., et al., Factors Predicting Recurrence of *Clostridium difficile* Infection (CDI) in Hospitalized Patients: Retrospective Study of More Than 2000 Patients. J Investig Med, 2015. **63**(5): p. 747-51.
120. Appaneal, H.J., et al., Predictors of *Clostridioides difficile* recurrence across a national cohort of veterans in outpatient, acute, and long-term care settings. Am J Health Syst Pharm, 2019. **76**(9): p. 581-590.
121. Avni, T., et al., *Clostridioides difficile* infection in immunocompromised hospitalized patients is associated with a high recurrence rate. Int J Infect Dis, 2020. **90**: p. 237-242.
122. Carpenter, B.P., et al., Identification of Factors Impacting Recurrent *Clostridium difficile* Infection and Development of a Risk Evaluation Tool. J Pharm Pharm Sci, 2016. **19**(3): p. 349-356.
123. Cobo, J., et al., Prediction of recurrent *clostridium difficile* infection at the bedside: the GEIH-CDI score. Int J Antimicrob Agents, 2018. **51**(3): p. 393-398.
124. D'Agostino, R.B., Sr., et al., Risk estimation for recurrent *Clostridium difficile* infection based on clinical factors. Clin Infect Dis, 2014. **58**(10): p. 1386-93.

125. Dharbhamulla, N., et al., *Risk Factors Associated With Recurrent Clostridium difficile Infection*. J Clin Med Res, 2019. **11**(1): p. 1-6.
126. Drekonja, D.M., et al., *Antimicrobial use and risk for recurrent Clostridium difficile infection*. Am J Med, 2011. **124**(11): p. 1081 e1-7.
127. Eyre, D.W., et al., *Predictors of first recurrence of Clostridium difficile infection: implications for initial management*. Clin Infect Dis, 2012. **55 Suppl 2**: p. S77-87.
128. Falcone, M., et al., *Risk factors for recurrence in patients with Clostridium difficile infection due to 027 and non-027 ribotypes*. Clin Microbiol Infect, 2019. **25**(4): p. 474-480.
129. Freedberg, D.E., et al., *Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients*. Am J Gastroenterol, 2013. **108**(11): p. 1794-801.
130. Fujii, L.F., J. Crowell, M. DiBaise, K., *Appendectomy and Risk of Clostridium difficile Recurrence*. Infectious Diseases in Clinical Practice, 2013. **21**(1): p. 28-32.
131. Hebert, C., et al., *Electronic health record-based detection of risk factors for Clostridium difficile infection relapse*. Infect Control Hosp Epidemiol, 2013. **34**(4): p. 407-14.
132. Im, G.Y., et al., *The appendix may protect against Clostridium difficile recurrence*. Clin Gastroenterol Hepatol, 2011. **9**(12): p. 1072-7.
133. Kimura, T., R. Snijder, and T. Sugitani, *Characterization and risk factors for recurrence of Clostridioides (Clostridium) difficile infection in Japan: A nationwide real-world analysis using a large hospital-based administrative dataset*. J Infect Chemother, 2019. **25**(8): p. 615-620.
134. Larrainzar-Coghen, T., et al., *First recurrence of Clostridium difficile infection: clinical relevance, risk factors, and prognosis*. Eur J Clin Microbiol Infect Dis, 2016. **35**(3): p. 371-8.
135. Lavergne, V., et al., *Lymphopenia as a novel marker of Clostridium difficile infection recurrence*. J Infect, 2013. **66**(2): p. 129-35.
136. Linsky, A., et al., *Proton pump inhibitors and risk for recurrent Clostridium difficile infection*. Arch Intern Med, 2010. **170**(9): p. 772-8.
137. Louie, T.J., et al., *Effect of age on treatment outcomes in Clostridium difficile infection*. J Am Geriatr Soc, 2013. **61**(2): p. 222-30.
138. Lupse, M., et al., *Predictors of first recurrence in Clostridium difficile-associated disease. A study of 306 patients hospitalized in a Romanian tertiary referral center*. J Gastrointest Liver Dis, 2013. **22**(4): p. 397-403.
139. Marincu, I., et al., *Predictive Factors for the First Recurrence of Clostridioides difficile Infection in the Elderly from Western Romania*. Medicina (Kaunas), 2020. **56**(9).
140. McDonald, E.G., et al., *Continuous Proton Pump Inhibitor Therapy and the Associated Risk of Recurrent Clostridium difficile Infection*. JAMA Intern Med, 2015. **175**(5): p. 784-91.
141. McFarland, L.V., et al., *Recurrent Clostridium difficile disease: epidemiology and clinical characteristics*. Infect Control Hosp Epidemiol, 1999. **20**(1): p. 43-50.
142. Na'amnih, W., et al., *Risk factors for recurrent Clostridium difficile infection in a tertiary hospital in Israel*. Eur J Clin Microbiol Infect Dis, 2018. **37**(7): p. 1281-1288.
143. Negrut, N., et al., *Risk Factors Associated with Recurrent Clostridioides difficile Infection*. Healthcare, 2020. **8**(3): p. 12.

144. Origüen, J., et al., *Toxin B PCR Amplification Cycle Threshold Adds Little to Clinical Variables for Predicting Outcomes in Clostridium difficile Infection: a Retrospective Cohort Study*. J Clin Microbiol, 2019. **57**(2).
145. Pepin, J., et al., *Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada*. Clin Infect Dis, 2005. **40**(11): p. 1591-7.
146. Rao, K., P.D.R. Higgins, and V.B. Young, *An Observational Cohort Study of Clostridium difficile Ribotype 027 and Recurrent Infection*. mSphere, 2018. **3**(3).
147. Reveles, K.R., et al., *Derivation and Validation of a Clostridium difficile Infection Recurrence Prediction Rule in a National Cohort of Veterans*. Pharmacotherapy, 2018. **38**(3): p. 349-356.
148. Rodriguez-Pardo, D., et al., *Epidemiology of Clostridium difficile infection and risk factors for unfavorable clinical outcomes: results of a hospital-based study in Barcelona, Spain*. J Clin Microbiol, 2013. **51**(5): p. 1465-73.
149. Rotramel, A., et al., *PPI therapy and albumin are better predictors of recurrent Clostridium difficile colitis than choice of antibiotics*. J Gastrointest Surg, 2012. **16**(12): p. 2267-73.
150. van Beurden, Y.H., et al., *Host factors are more important in predicting recurrent Clostridium difficile infection than ribotype and use of antibiotics*. Clin Microbiol Infect, 2018. **24**(1): p. 85 e1-85 e4.
151. Viswesh, V., et al., *Development of a bedside scoring system for predicting a first recurrence of Clostridium difficile-associated diarrhea*. Am J Health Syst Pharm, 2017. **74**(7): p. 474-482.
152. Zilberberg, M.D., et al., *Risk factors for recurrent Clostridium difficile infection (CDI) hospitalization among hospitalized patients with an initial CDI episode: a retrospective cohort study*. BMC Infect Dis, 2014. **14**: p. 306.
153. Cadena, J., et al., *Clinical predictors and risk factors for relapsing Clostridium difficile infection*. Am J Med Sci, 2010. **339**(4): p. 350-5.
154. Shakov, R., et al., *Diabetes mellitus as a risk factor for recurrence of Clostridium difficile infection in the acute care hospital setting*. Am J Infect Control, 2011. **39**(3): p. 194-8.
155. Ryu, H.S., et al., *Risk Factors for Recurrent Clostridium difficile Infection*. Intest Res, 2012. **10**(2): p. 176-182.
156. Golan, Y., et al., *Renal Impairment, C. difficile Recurrence, and the Differential Effect of Bezlotoxumab: A Post Hoc Analysis of Pooled Data From 2 Randomized Clinical Trials*. Open Forum Infect Dis, 2020. **7**(7): p. ofaa248.
157. Weiss, K., et al., *Effects of proton pump inhibitors and histamine-2 receptor antagonists on response to fidaxomicin or vancomycin in patients with Clostridium difficile-associated diarrhoea*. BMJ Open Gastroenterol, 2015. **2**(1): p. e000028.
158. Janarthanan, S., et al., *Clostridium difficile-associated diarrhea and proton pump inhibitor therapy: a meta-analysis*. Am J Gastroenterol, 2012. **107**(7): p. 1001-10.
159. Martinez, F.J., D.A. Leffler, and C.P. Kelly, *Clostridium difficile outbreaks: prevention and treatment strategies*. Risk Manag Healthc Policy, 2012. **5**: p. 55-64.
160. Olson, M.M., et al., *Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991*. Infect Control Hosp Epidemiol, 1994. **15**(6): p. 371-81.

161. Teasley, D.G., et al., *Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis*. Lancet, 1983. **2**(8358): p. 1043-6.
162. Wenisch, C., et al., *Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea*. Clin Infect Dis, 1996. **22**(5): p. 813-8.
163. Zar, F.A., et al., *A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity*. Clin Infect Dis, 2007. **45**(3): p. 302-7.
164. Johnson, S., et al., *Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials*. Clin Infect Dis, 2014. **59**(3): p. 345-54.
165. Allegretti, J.R., et al., *Clinical Predictors of Recurrence After Primary Clostridioides difficile Infection: A Prospective Cohort Study*. Dig Dis Sci, 2019.
166. Louie, T.J., et al., *Fidaxomicin versus vancomycin for Clostridium difficile infection*. N Engl J Med, 2011. **364**(5): p. 422-31.
167. Cornely, O.A., et al., *Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial*. Lancet Infect Dis, 2012. **12**(4): p. 281-9.
168. Cornely, O.A., et al., *Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin*. J Clin Oncol, 2013. **31**(19): p. 2493-9.
169. Housman, S.T., et al., *Assessment of Clostridium difficile Burden in Patients Over Time With First Episode Infection Following Fidaxomicin or Vancomycin*. Infect Control Hosp Epidemiol, 2016. **37**(2): p. 215-8.
170. Mikamo, H., et al., *Efficacy and safety of fidaxomicin for the treatment of Clostridioides (Clostridium) difficile infection in a randomized, double-blind, comparative Phase III study in Japan*. J Infect Chemother, 2018. **24**(9): p. 744-752.
171. Louie, T.J., et al., *OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection*. Antimicrob Agents Chemother, 2009. **53**(1): p. 261-3.
172. Tannock, G.W., et al., *A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin*. Microbiology (Reading), 2010. **156**(Pt 11): p. 3354-3359.
173. Stranges, P.M., D.W. Hutton, and C.D. Collins, *Cost-Effectiveness Analysis Evaluating Fidaxomicin versus Oral Vancomycin for the Treatment of Clostridium difficile Infection in the United States*. Value in Health, 2013. **16**(2): p. 297-304.
174. Markovic, V., et al., *Cost-Effectiveness Comparison of Fidaxomicin and Vancomycin for Treatment of Clostridium difficile Infection: A Markov Model Based on Data from a South West Balkan Country in Socioeconomic Transition*. Value in Health Regional Issues, 2014. **4**(1): p. 87-94.
175. Chen, J., et al., *Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection*. Clin Microbiol Infect, 2021.
176. Nathwani, D., et al., *Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection*. Journal of Antimicrobial Chemotherapy, 2014. **69**(11): p. 2901-2912.

177. Watt, M., et al., *A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany*. Infection, 2016. **44**(5): p. 599-606.
178. Watt, M., et al., *Cost-effectiveness analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection in France*. J Med Econ, 2017. **20**(7): p. 678-686.
179. Cornely, O.A., et al., *Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients aged ≥ 60 years (EXTEND): analysis of cost-effectiveness*. J Antimicrob Chemother, 2018. **73**(9): p. 2529-2539.
180. Rubio-Terres, C., et al., *Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain*. Eur J Clin Microbiol Infect Dis, 2019. **38**(6): p. 1105-1111.
181. Fekety, R., et al., *Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens*. Am J Med, 1989. **86**(1): p. 15-9.
182. Gonzales, M., et al., *Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection*. BMC Infect Dis, 2010. **10**: p. 363.
183. Cimolai, N., *Does oral vancomycin use necessitate therapeutic drug monitoring?* Infection, 2020. **48**(2): p. 173-182.
184. Guery, B., et al., *Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial*. Lancet Infect Dis, 2018. **18**(3): p. 296-307.
185. Wilcox, M.H., et al., *Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection*. N Engl J Med, 2017. **376**(4): p. 305-317.
186. Gerding, D.N., et al., *Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection in Patients at Increased Risk for Recurrence*. Clin Infect Dis, 2018. **67**(5): p. 649-656.
187. Merck Sharp & Dome Corp. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761046s000lbl.pdf.
188. Prabhu, V.S., et al., *Cost-effectiveness of Bezlotoxumab Compared With Placebo for the Prevention of Recurrent Clostridium difficile Infection*. Clin Infect Dis, 2018. **66**(3): p. 355-362.
189. Salavert, M., et al., *Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain*. Advances in Therapy, 2018. **35**(11): p. 1920-1934.
190. Vickers, R.J., et al., *Efficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study*. Lancet Infect Dis, 2017. **17**(7): p. 735-744.
191. Nct, *A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)*. <https://clinicaltrials.gov/show/nct02784002>, 2016.
192. Gerding, D.N., et al., *Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials*. Lancet Infect Dis, 2019. **19**(3): p. 265-274.

193. Boix, V., et al., *Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomylin in Subjects With Clostridium difficile Infection*. Open Forum Infect Dis, 2017. **4**(1): p. ofw275.
194. Mullane, K., et al., *Multicenter, randomized clinical trial to compare the safety and efficacy of LFF571 and vancomycin for Clostridium difficile infections*. Antimicrob Agents Chemother, 2015. **59**(3): p. 1435-40.
195. Vehreschild, M., et al., *Fidaxomicin for the treatment of Clostridium difficile infection (CDI) in at-risk patients with inflammatory bowel disease, fulminant CDI, renal impairment or hepatic impairment: a retrospective study of routine clinical use (ANEMONE)*. Eur J Clin Microbiol Infect Dis, 2018. **37**(11): p. 2097-2106.
196. Gentry, C.A., et al., *Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study*. Clin Microbiol Infect, 2019. **25**(8): p. 987-993.
197. Penziner, S., et al., *Fidaxomicin therapy in critically ill patients with Clostridium difficile infection*. Antimicrobial Agents and Chemotherapy, 2015. **59**(3): p. 1776-1781.
198. Pichenot, M., et al., *Fidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital*. Infection, 2017. **45**(4): p. 425-431.
199. Wang, Y., et al., *Does Addition of Intravenous Metronidazole to Oral Vancomycin Improve Outcomes in Clostridioides difficile Infection?* Clin Infect Dis, 2019.
200. Wenisch, J.M., et al., *Prospective observational study comparing three different treatment regimes in patients with Clostridium difficile infection*. Antimicrob Agents Chemother, 2012. **56**(4): p. 1974-8.
201. Vega, A.D., et al., *Evaluation of Addition of Intravenous Metronidazole to Oral Vancomycin Therapy in Critically Ill Patients with Non-Fulminant Severe Clostridioides difficile Infection*. Pharmacotherapy, 2020. **40**(5): p. 398-407.
202. Rokas, K.E., et al., *The Addition of Intravenous Metronidazole to Oral Vancomycin is Associated With Improved Mortality in Critically Ill Patients With Clostridium difficile Infection*. Clin Infect Dis, 2015. **61**(6): p. 934-41.
203. Gergely Szabo, B., et al., *Use of intravenous tigecycline in patients with severe Clostridium difficile infection: a retrospective observational cohort study*. Clin Microbiol Infect, 2016. **22**(12): p. 990-995.
204. Manea, E., et al., *The role of tigecycline in the management of Clostridium difficile infection: a retrospective cohort study*. Clin Microbiol Infect, 2018. **24**(2): p. 180-184.
205. Kechagias, K.S., et al., *Tigecycline for the treatment of patients with Clostridium difficile infection: an update of the clinical evidence*. Eur J Clin Microbiol Infect Dis, 2020. **39**(6): p. 1053-1058.
206. Stewart, D.B., C.S. Hollenbeak, and M.Z. Wilson, *Is colectomy for fulminant Clostridium difficile colitis life saving? A systematic review*. Colorectal Dis, 2013. **15**(7): p. 798-804.
207. Neal, M.D., et al., *Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease*. Ann Surg, 2011. **254**(3): p. 423-7; discussion 427-9.
208. Ferrada, P., et al., *Loop ileostomy versus total colectomy as surgical treatment for Clostridium difficile-associated disease: An Eastern Association for the Surgery of Trauma multicenter trial*. J Trauma Acute Care Surg, 2017. **83**(1): p. 36-40.

209. Hall, B.R., et al., *No survival advantage exists for patients undergoing loop ileostomy for clostridium difficile colitis*. Am J Surg, 2019. **217**(1): p. 34-39.
210. Juo, Y.Y., et al., *Trends in Diverting Loop Ileostomy vs Total Abdominal Colectomy as Surgical Management for Clostridium Difficile Colitis*. JAMA Surg, 2019.
211. Akamine, C.M., et al., *The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series*. BMC Infect Dis, 2016. **16**: p. 316.
212. Freeman, J., et al., *Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes*. Clin Microbiol Infect, 2015. **21**(3): p. 248 e9-248 e16.
213. Terveer, E.M., et al., *Faecal microbiota transplantation for Clostridioides difficile infection: Four years' experience of the Netherlands Donor Feces Bank*. United European Gastroenterol J, 2020. **8**(10): p. 1236-1247.
214. Fischer, M., et al., *Fecal microbiota transplant in severe and severe-complicated Clostridium difficile: A promising treatment approach*. Gut Microbes, 2017. **8**(3): p. 289-302.
215. Ianiro, G., et al., *Randomised clinical trial: faecal microbiota transplantation by colonoscopy plus vancomycin for the treatment of severe refractory Clostridium difficile infection-single versus multiple infusions*. Aliment Pharmacol Ther, 2018. **48**(2): p. 152-159.
216. Rupawala, A.H., et al., *Management of Severe and Severe/Complicated Clostridoides difficile Infection using Sequential Fecal Microbiota Transplant by Retention Enema*. Clin Infect Dis, 2021.
217. Cornely, O.A., et al., *Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin*. Clin Infect Dis, 2012. **55 Suppl 2**: p. S154-61.
218. Spiceland, C.M., S. Khanna, and D.S. Pardi, *Outcomes With Fidaxomicin Therapy in Clostridium difficile Infection*. J Clin Gastroenterol, 2018. **52**(2): p. 151-154.
219. McFarland, L.V., G.W. Elmer, and C.M. Surawicz, *Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease*. Am J Gastroenterol, 2002. **97**(7): p. 1769-75.
220. Hota, S.S., et al., *Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial*. Clin Infect Dis, 2017. **64**(3): p. 265-271.
221. Major, G., et al., *Follow-on RifAxiMin for the Prevention of recurrence following standard treatment of Infection with Clostridium Difficile (RAPID): a randomised placebo controlled trial*. Gut, 2019. **68**(7): p. 1224-1231.
222. Freeman, J., et al., *Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study*. Eur J Clin Microbiol Infect Dis, 2020. **39**(1): p. 169-177.
223. Hvas, C.L., et al., *Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection*. Gastroenterology, 2019. **156**(5): p. 1324-1332.e3.
224. Oksi, J., et al., *Real-world efficacy of bezlotoxumab for prevention of recurrent Clostridium difficile infection: a retrospective study of 46 patients in five university hospitals in Finland*. Eur J Clin Microbiol Infect Dis, 2019. **38**(10): p. 1947-1952.
225. Escudero-Sánchez, R., et al., *Real-World Experience with Bezlotoxumab for Prevention of Recurrence of Clostridioides difficile Infection*. J Clin Med, 2020. **10**(1).

226. Hengel, R.L., et al., *Real-world Experience of Bezlotoxumab for Prevention of Clostridioides difficile Infection: A Retrospective Multicenter Cohort Study*. Open Forum Infect Dis, 2020. **7**(4): p. ofaa097.
227. Cammarota, G., et al., *Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs. vancomycin for the treatment of recurrent Clostridium difficile infection*. Aliment Pharmacol Ther, 2015. **41**(9): p. 835-43.
228. Kelly, C.R., et al., *Effect of Fecal Microbiota Transplantation on Recurrence in Multiply Recurrent Clostridium difficile Infection: A Randomized Trial*. Ann Intern Med, 2016. **165**(9): p. 609-616.
229. van Nood, E., et al., *Duodenal infusion of donor feces for recurrent Clostridium difficile*. N Engl J Med, 2013. **368**(5): p. 407-15.
230. Jiang, Z.D., et al., *Randomised clinical trial: faecal microbiota transplantation for recurrent Clostridium difficile infection - fresh, or frozen, or lyophilised microbiota from a small pool of healthy donors delivered by colonoscopy*. Aliment Pharmacol Ther, 2017. **45**(7): p. 899-908.
231. Jiang, Z.D., et al., *Safety and preliminary efficacy of orally administered lyophilized fecal microbiota product compared with frozen product given by enema for recurrent Clostridium difficile infection: A randomized clinical trial*. PLoS One, 2018. **13**(11): p. e0205064.
232. Kao, D., et al., *Effect of Oral Capsule- vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent Clostridium difficile Infection: A Randomized Clinical Trial*. Jama, 2017. **318**(20): p. 1985-1993.
233. Youngster, I., et al., *Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study*. Clin Infect Dis, 2014. **58**(11): p. 1515-22.
234. Lee, C.H., et al., *Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial*. Jama, 2016. **315**(2): p. 142-9.
235. Kelly, C.R., et al., *Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry*. Gastroenterology, 2021. **160**(1): p. 183-+.
236. Keller, J.J., et al., *A standardised model for stool banking for faecal microbiota transplantation: a consensus report from a multidisciplinary UEG working group*. United European Gastroenterol J, 2020: p. 2050640620967898.
237. Ianiro, G., et al., *Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic*. Gut, 2020. **69**(9): p. 1555-1563.
238. Vendrik, K.E.W., et al., *Periodic screening of donor faeces with a quarantine period to prevent transmission of multidrug-resistant organisms during faecal microbiota transplantation: a retrospective cohort study*. Lancet Infect Dis, 2020.
239. Terveer, E.M., et al., *How to: Establish and run a stool bank*. Clin Microbiol Infect, 2017. **23**(12): p. 924-930.
240. Zellmer, C., et al., *Shiga Toxin-Producing Escherichia coli Transmission via Fecal Microbiota Transplant*. Clin Infect Dis, 2020.
241. DeFilipp, Z., et al., *Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant*. N Engl J Med, 2019. **381**(21): p. 2043-2050.


242. Drewes, J.L., et al., *Transmission and clearance of potential procarcinogenic bacteria during fecal microbiota transplantation for recurrent Clostridioides difficile*. JCI Insight, 2019. **4**(19).
243. Terveer, E.M., et al., *Human transmission of Blastocystis by Fecal Microbiota Transplantation without development of gastrointestinal symptoms in recipients*. Clin Infect Dis, 2019.
244. Allegretti, J.R., et al., *Inflammatory Bowel Disease Outcomes Following Fecal Microbiota Transplantation for Recurrent C. difficile Infection*. Inflamm Bowel Dis, 2020.
245. Terveer, E.M., et al., *Faecal microbiota transplantation for Clostridioides difficile infection: Four years' experience of the Netherlands Donor Feces Bank*. United European Gastroenterol J, 2020: p. 2050640620957765.
246. Garey, K.W., et al., *Meta-analysis to assess risk factors for recurrent Clostridium difficile infection*. J Hosp Infect, 2008. **70**(4): p. 298-304.
247. Tariq, R., et al., *Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis*. JAMA Intern Med, 2017. **177**(6): p. 784-791.
248. Mehta, P., R.G. Nahass, and L. Brunetti, *Acid suppression medications during hospitalization as a risk factor for recurrence of Clostridioides difficile infection: systematic review and meta-analysis*. Clin Infect Dis, 2020.
249. D'Silva, K.M., et al., *Proton pump inhibitor use and risk for recurrent Clostridioides difficile infection: a systematic review and meta-analysis*. Clin Microbiol Infect, 2021.
250. Crook, D.W., et al., *Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials*. Clin Infect Dis, 2012. **55 Suppl 2**: p. S93-103.
251. Thibault, A., M.A. Miller, and C. Gaese, *Risk factors for the development of Clostridium difficile-associated diarrhea during a hospital outbreak*. Infect Control Hosp Epidemiol, 1991. **12**(6): p. 345-8.
252. Johnson, S., et al., *Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals*. N Engl J Med, 1999. **341**(22): p. 1645-51.
253. Loo, V.G., et al., *A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality*. N Engl J Med, 2005. **353**(23): p. 2442-9.
254. Muto, C.A., et al., *A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use*. Infect Control Hosp Epidemiol, 2005. **26**(3): p. 273-80.
255. Pepin, J., et al., *Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec*. Clin Infect Dis, 2005. **41**(9): p. 1254-60.
256. Hensgens, M.P., et al., *Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics*. J Antimicrob Chemother, 2012. **67**(3): p. 742-8.
257. Goldenberg, J.Z., et al., *Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children*. Cochrane Database Syst Rev, 2017. **12**: p. Cd006095.
258. Wombwell, E., et al., *The effect of Saccharomyces boulardii primary prevention on risk of Hospital Onset Clostridioides difficile infection in hospitalized patients*

- administered antibiotics frequently associated with Clostridioides difficile infection.* Clin Infect Dis, 2020.
259. Allen, S.J., et al., *Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial.* Lancet, 2013. **382**(9900): p. 1249-57.
 260. Suez, J., et al., *Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.* Cell, 2018. **174**(6): p. 1406-1423 e16.
 261. Besselink, M.G., et al., *Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial.* Lancet, 2008. **371**(9613): p. 651-659.
 262. Carignan, A., et al., *Efficacy of Secondary Prophylaxis With Vancomycin for Preventing Recurrent Clostridium difficile Infections.* Am J Gastroenterol, 2016. **111**(12): p. 1834-1840.
 263. Van Hise, N.W., et al., *Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.* Clin Infect Dis, 2016. **63**(5): p. 651-3.
 264. Bajrovic, V., et al., *Vancomycin prophylaxis for Clostridium difficile infection among lung transplant recipients.* Journal of Heart and Lung Transplantation, 2019. **38**(8): p. 874-876.
 265. Caroff, D.A., et al., *Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridioides difficile infection relapses.* Infect Control Hosp Epidemiol, 2019. **40**(6): p. 662-667.
 266. Ganetsky, A., et al., *Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.* Clin Infect Dis, 2019. **68**(12): p. 2003-2009.
 267. Knight, E.M., et al., *Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence.* J Pharm Pract, 2019: p. 897190019825994.
 268. Morrisette, T., et al., *Oral Vancomycin Prophylaxis as Secondary Prevention Against Clostridioides difficile Infection in the Hematopoietic Stem Cell Transplantation and Hematologic Malignancy Population.* Biol Blood Marrow Transplant, 2019. **25**(10): p. 2091-2097.
 269. Johnson, S.W., S.V. Brown, and D.H. Priest, *Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure.* Clin Infect Dis, 2020. **71**(5): p. 1133-1139.
 270. Mullane, K.M., et al., *A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile-associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation.* Clinical Infectious Diseases, 2019. **68**(2): p. 196-203.
 271. Nerandzic, M.M., et al., *Reduced acquisition and overgrowth of vancomycin-resistant enterococci and Candida species in patients treated with fidaxomicin versus vancomycin for Clostridium difficile infection.* Clin Infect Dis, 2012. **55** Suppl 2: p. S121-6.

272. Warren, C.A., et al., *Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice*. Antimicrob Agents Chemother, 2013. **57**(2): p. 689-96.
273. Knight, E.M., et al., *Long-Term Efficacy of Oral Vancomycin Prophylaxis for the Prevention of Clostridium difficile Recurrence*. J Pharm Pract, 2020. **33**(5): p. 633-639.
274. Zacharioudakis, I.M., et al., *Oral vancomycin prophylaxis against recurrent Clostridioides difficile infection: Efficacy and side effects in two hospitals*. Infect Control Hosp Epidemiol, 2020. **41**(8): p. 908-913.
275. Kokai-Kun, J.F., et al., *Use of ribaxamase (SYN-004), a beta-lactamase, to prevent Clostridium difficile infection in beta-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial*. Lancet Infect Dis, 2019. **19**(5): p. 487-496.
276. de Bruyn, G., et al., *Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial*. Lancet Infect Dis, 2021. **21**(2): p. 252-262.
277. Optimer Pharmaceuticals Inc. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/201699s000lbl.pdf.
278. ViroPharma Incorporated. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050606s028lbl.pdf.
279. Pfizer Inc. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/012623s061lbl.pdf.
280. Ani Pharmaceuticals Inc. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/060180s047lbl.pdf.
281. Xellia Pharmaceuticals. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211962s000lbl.pdf.
282. Mylan Laboratories Limited. 2020/11/26]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/209481s000lbl.pdf.
283. Shue, Y.K., et al., *Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses*. Antimicrob Agents Chemother, 2008. **52**(4): p. 1391-5.
284. Ford, D.C., et al., *Cost-effectiveness analysis of initial treatment strategies for mild-to-moderate Clostridium difficile infection in hospitalized patients*. Am J Health Syst Pharm, 2018. **75**(15): p. 1110-1121.
285. Varier, R.U., et al., *Cost-Effectiveness Analysis of Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection*. Infection Control and Hospital Epidemiology, 2015. **36**(4): p. 438-444.
286. Lapointe-Shaw, L., et al., *Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection*. Plos One, 2016. **11**(2): p. 18.
287. Baro, E., et al., *Cost-effectiveness analysis of five competing strategies for the management of multiple recurrent community-onset Clostridium difficile infection in France*. PLoS ONE, 2017. **12** (1) (no pagination)(e0170258).
288. Cornely, O.A., et al., *Exploratory Evaluation of Bezlotoxumab on Outcomes Associated With Clostridioides difficile Infection in MODIFY I/II Participants With Cancer*. Open Forum Infect Dis, 2020. **7**(2): p. ofaa038.
289. Daley, P., et al., *Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial*. J Antimicrob Chemother, 2017. **72**(12): p. 3462-3470.

290. Dubberke, E.R., et al., *Efficacy of Bezlotoxumab in Participants Receiving Metronidazole, Vancomycin, or Fidaxomicin for Treatment of Clostridioides (Clostridium) difficile Infection*. Open Forum Infect Dis, 2020. **7**(6): p. ofaa157.
291. Gerding, D.N., et al., *Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial*. Jama, 2015. **313**(17): p. 1719-27.
292. Kelly, C.P., et al., *Bezlotoxumab for Clostridium difficile Infection Complicating Inflammatory Bowel Disease*. Gastroenterology, 2018. **155**(4): p. 1270-1271.
293. Lee, C.H., et al., *Surotomyacin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial*. J Antimicrob Chemother, 2016. **71**(10): p. 2964-71.
294. Louie, T., et al., *Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection*. Antimicrob Agents Chemother, 2015. **59**(10): p. 6266-73.
295. Allegretti, J.R., et al., *Outcomes of Fecal Microbiota Transplantation in Patients With Inflammatory Bowel Diseases and Recurrent Clostridioides difficile Infection*. Gastroenterology, 2020. **159**(5): p. 1982-1984.
296. Chin, S.M., et al., *Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Patients With Inflammatory Bowel Disease: A Single-Center Experience*. Clin Gastroenterol Hepatol, 2017. **15**(4): p. 597-599.
297. Dubberke, E.R., et al., *Results From a Randomized, Placebo-Controlled Clinical Trial of a RBX2660-A Microbiota-Based Drug for the Prevention of Recurrent Clostridium difficile Infection*. Clin Infect Dis, 2018. **67**(8): p. 1198-1204.
298. Ianiro, G., et al., *Predictors of failure after single faecal microbiota transplantation in patients with recurrent Clostridium difficile infection: results from a 3-year, single-centre cohort study*. Clin Microbiol Infect, 2017. **23**(5): p. 337.e1-337.e3.
299. Martinez, C., J. Edwards, and A. Hassoun, *Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection*. Infect Dis (Lond), 2018. **50**(11-12): p. 864-867.
300. McGovern, B.H., et al., *SER-109, an Investigational Microbiome Drug to Reduce Recurrence after Clostridioides difficile infection: lessons Learned from a Phase 2 Trial*. Clinical infectious diseases, 2020.
301. Orenstein, R., et al., *Safety and Durability of RBX2660 (Microbiota Suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study*. Clin Infect Dis, 2016. **62**(5): p. 596-602.
302. Satokari, R., et al., *Simple faecal preparation and efficacy of frozen inoculum in faecal microbiota transplantation for recurrent Clostridium difficile infection--an observational cohort study*. Aliment Pharmacol Ther, 2015. **41**(1): p. 46-53.
303. Reigadas, E., et al., *Faecal microbiota transplantation for recurrent Clostridioides difficile infection: experience with lyophilized oral capsules*. J Hosp Infect, 2020. **105**(2): p. 319-324.
304. Staley, C., et al., *Successful Resolution of Recurrent Clostridium difficile Infection using Freeze-Dried, Encapsulated Fecal Microbiota; Pragmatic Cohort Study*. Am J Gastroenterol, 2017. **112**(6): p. 940-947.
305. Youngster, I., et al., *Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection*. Jama, 2014. **312**(17): p. 1772-8.

306. Youngster, I., et al., *Oral, frozen fecal microbiota transplant (FMT) capsules for recurrent Clostridium difficile infection*. BMC Med, 2016. **14**(1): p. 134.
307. Popovic, N., et al., *Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study*. Eur J Clin Microbiol Infect Dis, 2018. **37**(4): p. 745-754.
308. Ehrhardt, S., et al., *Saccharomyces boulardii to prevent antibiotic-associated diarrhea: A randomized, double-masked, placebo-controlled trial*. Open Forum Infectious Diseases, 2016. **3** (1) (no pagination)(ofw011).
309. Helps, A., E. Bell, and R. Mactier, *Prospective randomized double-blind study of efficacy of probiotic milk drink in reducing the incidence of antibiotic-associated diarrhoea and clostridium difficile Diarrhoea*. International Journal of Probiotics and Prebiotics, 2016. **11**(2): p. 145-152.
310. Ouwehand, A.C., et al., *Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study*. Vaccine, 2014. **32**(4): p. 458-63.
311. Rajkumar, C., et al., *Do Probiotics prevent antibiotic associated diarrhoea? Results of a multicentre randomised placebo-controlled trial*. J Hosp Infect, 2020.
312. Selinger, C.P., et al., *Probiotic VSL#3 prevents antibiotic-associated diarrhoea in a double-blind, randomized, placebo-controlled clinical trial*. J Hosp Infect, 2013. **84**(2): p. 159-65.
313. Tobar-Marcillo, M., et al., *Metronidazole in the prevention of antibiotic-associated diarrhoea and Clostridium difficile infection in high-risk hospitalised patients*. Gastroenterol Hepatol, 2018. **41**(6): p. 362-368.

FIGURE 1 SUGGESTED TREATMENT ALGORITHM

* Risk stratification for risk of recurrence may be applied for selective use of fidaxomicin in case of limited access or resources.

** Consider extended fidaxomicin: 200 mg bid on day 1-5, 200 mg q48h on day 7-25. Most important risk factor for recurrence is age >65-70 years. Additional risk factor(s) to consider are healthcare-associated CDI, prior hospitalization ≤ 3 months, prior CDI episode, continued non-CDI antibiotic use, and PPI therapy. The risk of recurrence is assumed higher with more risk factors present.

^{\$} Vancomycin taper and pulse: 2 weeks 125 mg qid, followed by 1 week 125 mg bid, then 1 week 125 mg qd, then 1 week 125 mg q48h, and finally 125 mg q72h for 1 week.

^{\$\$} Rectal or nasoduodenal delivery

TABLE 1 Question: Metronidazole compared to vancomycin for initial CDI

Certainty assessment							№ of patients		Effect		Certainty	References
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	metronidazole	vancomycin	Relative (95% CI)	Absolute (95% CI)		
Treatment response												
5	randomised trials	not serious	serious ^a	not serious	not serious	none	336/430 (78.1%)	359/413 (86.9%)	RR 0.90 (0.84 to 0.96)	87 fewer per 1.000 (from 139 fewer to 35 fewer)	⊕⊕⊕○ MODERATE	Teasley 1983 [161] Wenisch 1996 [162] Zar 2007 [163] Johnson 2014 [164]
Recurrence (follow up: range 21 days to 30 days)												
5	randomised trials	not serious	serious ^a	not serious	not serious	none	59/343 (17.2%)	65/362 (18.0%)	RR 0.96 (0.70 to 1.32)	7 fewer per 1.000 (from 54 fewer to 57 more)	⊕⊕⊕○ MODERATE	Teasley 1983 [161] Wenisch 1996 [162] Zar 2007 [163] Johnson 2014 [164]

CI: Confidence interval; RR: Risk ratio

Explanations

a. Equivalence in 2 RCTs before 2000 (N≤45 per treatment group) by Teasley and Wenisch, and in mild subgroup by Zar. Metronidazole inferior in pooled analysis of 2 RCTs by Johnson.

TABLE 2

Question: Fidaxomicin compared to vancomycin for initial CDI

Certainty assessment							№ of patients		Effect		Certainty	References
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	fidaxomicin	vancomycin	Relative (95% CI)	Absolute (95% CI)		
Treatment response												
3	randomised trials	not serious	not serious	not serious	not serious	none	327/374 (87.4%)	336/405 (83.0%)	RR 1.05 (0.99 to 1.12)	41 more per 1.000 (from 8 fewer to 100 more)	⊕⊕⊕⊕ HIGH	Louie 2011 [166] Cornely 20212 [167] Mikamo 2018 [170]
Recurrence (follow up: 28 days)												
3	randomised trials	not serious	serious ^a	not serious	not serious	none	49/327 (15.0%)	88/336 (26.2%)	RR 0.57 (0.42 to 0.78)	113 fewer per 1.000 (from 152 fewer to 58 fewer)	⊕⊕⊕○ MODERATE	Louie 2011 [166] Cornely 20212 [167] Mikamo 2018 [170]

CI: Confidence interval; RR: Risk ratio

Explanations

a. Significantly higher global/sustained cure rates with fidaxomicin in the studies by Louie and Cornely. No difference in primary endpoint of global (sustained) cure by Mikamo; considerable loss to follow-up in this study.

TABLE 3

Question: Extended fidaxomicin compared to vancomycin for initial CDI

Certainty assessment							№ of patients		Effect		Certainty	References
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	extended fidaxomicin	vancomycin	Relative (95% CI)	Absolute (95% CI)		
Treatment response												
1	randomised trial	serious ^a	not serious	not serious	not serious	none	138/177 (78.0%)	147/179 (82.1%)	RR 0.95 (0.86 to 1.05)	41 fewer per 1.000 (from 115 fewer to 41 more)	⊕⊕⊕○ MODERATE	Guery 2018 [184]
Recurrence (follow up: 30 days)												
1	randomised trial	serious ^a	not serious	not serious	not serious	none	14/138 (10.1%)	41/147 (27.9%)	RR 0.36 (0.21 to 0.64)	179 fewer per 1.000 (from 220 fewer to 100 fewer)	⊕⊕⊕○ MODERATE	Guery 2018 [184]

CI: Confidence interval; RR: Risk ratio

Explanations

a. Considerable loss to follow-up and discontinuation of treatment.

TABLE 4

Question: SoC plus bezlotoxumab compared to SoC alone for (increased risk of) recurrent CDI

Certainty assessment							№ of patients		Effect		Certainty	References
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	SoC plus bezlotoxumab	SoC alone	Relative (95% CI)	Absolute (95% CI)		
Treatment response												
2	randomised trials	not serious	not serious	serious ^a	not serious	none	625/781 (80.0%)	621/773 (80.3%)	RR 1.00 (0.95 to 1.05)	0 fewer per 1.000 (from 40 fewer to 40 more)	⊕⊕⊕○ MODERATE	Wilcox 2017 [185]
Recurrence (follow up: 12 weeks)												
2	randomised trials	not serious	not serious	serious ^a	not serious	none	129/625 (20.6%)	206/621 (33.2%)	RR 0.62 (0.51 to 0.75)	126 fewer per 1.000 (from 163 fewer to 83 fewer)	⊕⊕⊕○ MODERATE	Wilcox 2017 [185]

CI: Confidence interval; RR: Risk ratio

Explanations

a. The trials included 72% initial CDI and 28% recurrent CDI. Post-hoc analysis of pre-specified risk factors for recurrence revealed that reduction of recurrence was 25% (95%CI -39 to -9) in patients with >=3 risk factors, and 2% (-11 to 7) in patients with no risk factors .

TABLE 5

Question: FMT (after ≥ 3 days vancomycin pre-treatment) compared to vancomycin alone for multiple recurrent CDI

Certainty assessment							No of patients		Effect		Certainty	References
No of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	FMT (after ≥ 3 days vancomycin pre-treatment)	vancomycin alone	Relative (95% CI)	Absolute (95% CI)		
3	randomised trials	serious ^a	not serious	not serious	serious ^b	strong association	35/44 (79.5%)	11/35 (31.4%)	RR 2.53 (1.52 to 4.22)	481 more per 1.000 (from 163 more to 1.000 more)	⊕⊕⊕○ MODERATE	Van Nood 2013 [229] Camarota 2015 [227] Hvas 2019 [223]

CI: Confidence interval; RR: Risk ratio

Explanations

- a. Unblinded trials.
b. Small sample sizes.